Investigation of the role of prion protein in protection against transition metal induced toxicity by HASH(0x55b51a131e60)
1 
 
Investigation of the role of prion protein in protection 
against transition metal induced toxicity 
 
 
 
 
 
Ph.D. Thesis 
 
 
 
 
 
 
Pradeep Kumar Reddy Cingaram 
 
 
 
 
 
 
Supervisor: Dr. Ervin Welker 
Co-supervisor: Dr. Elfrieda Fodor 
 
 
 
 
 
 
 
Doctoral School of Biology 
University of Szeged 
 
 
 
Institute of Biochemistry 
Biological Research Center of the Hungarian Academy of Sciences 
 
 
 
Szeged, 2016 
 
2 
 
Table of contents 
List of abbreviations……………………………………………………….…………………4 
List of figures……………………………………………………………….…………………6 
1. Introduction…………………………………………………………………………….....8 
1.1. The prion protein ………………………………………………………………….....9 
1.1.1. Prion protein’s structure……………………………………………………….9 
1.1.2. PRNP and its paralogs…………………………………………………...……11 
1.1.3. Prion protein localization……………………………………………………..14 
1.1.4. Trafficking: PrPC endocytosis pathways…………………………………...…14 
1.2. Conformational transition from PrPC to PrPSc……………………………………….16 
1.3. Functions of PrPC………………………………………………………………….…20 
1.3.1. PrP – metal relations………………………………………………………….20 
1.3.2. Role of divalent cations in the pathogenesis of prion diseases……………….23 
1.3.3. PrP functions as antioxidant ………………………………………………….24 
2. Main objectives of the thesis……………………………………………………………..26 
3. Materials and Methods…………………………………………………………………..27 
3.1. Reagents and antibodies……………………………………………………………..27 
3.2. Cell culturing, transfection and generation of stable cell lines……………………...27 
3.3. Western blot analysis………………………………………………………………..28 
3.4. Immunocytochemistry…………………………………………………………...…29  
3.5. Metal ion treatment of cells…………………………………………………………30 
3.6. Cell viability assays and cell morphology…………………………………………..30 
3.7. Cell-death assays…………………………………………………………………….31 
3.8. Statistical analysis…………………………………………………………………...31 
3 
 
4. Results…………………………………………………………………………………….32 
4.1 ZW 13–2 cells are significantly more resistant to Cu2+, Zn2+, Mn2+ and Co2+ induced 
toxicities than Zpl 2–1 cells……………………………………………………………...32 
4.2 ZW 13–2 cells are morphologically less affected by Cu2+, Zn2+, Mn2+  and Co2+ 
induced stresses than  Zpl 2–1 cells……………………………………………………...37 
4.3 Generation of stable prion protein expressing Prnp
−/−
 (Zpl 2-1) neuronal cell lines..40 
4.4 Zpl 2–1-PrP cells are not significantly more resistant to Cu2+, Zn2+, Mn2+and 
Co
2+
 induced toxicities than its control Zpl 2-1-vector cells…………………………….44 
4.5 Zpl 2–1-PrP cells are not less affected morphologically by Cu2+, Zn2+, Mn2+ and 
Co
2+
 induced stresses than its control Zpl 2-1-vector cells………………………………51 
4.6 Zpl 2-1-PrP cells are not more resistant to Cu
+2
, Zn
+2
 and Co
+2
 induced cell death than 
Zpl 2-1-vector cells, whereas, PrP expressing ZW cells are more resistant compared to 
the PrP ablated Zpl 2-1 cells……………………………………………………………..54 
4.7 SH-SY5Y-PrP cells are significantly more resistant to Cu
2+
 and Mn
2+
 induced 
toxicities than SH-SY5Y and SH-SY5Y-vector cells……………………………………60 
5. Discussion………………………..………………………………………………………...67 
6. Conclusions………………………………………………………………………………..75 
7. References…………………………………………………………………………………77 
8. Acknowledgement………………………………………………………………………..89 
9. Summary…………………………………………………………………………………..91 
10. Összefoglalás……………………………………………………………………………..93 
11. Appendix..………………………………………………………………………………..95 
 
    
 
4 
 
List of abbreviations 
aa: Amino acids 
BSA: Bovine serum albumin 
BSE: Bovine spongiform encephalopathy 
CJD: Creutzfeldt-Jakob disease 
CNS: Central nervous system 
CWD: Chronic wasting disease 
DAPI: 4′, 6-diamidino-2 phenylindole 
DMEM: Dulbecco's Modified Eagle's Medium 
ECL: Enhances chemiluminescence 
EDTA: Ethylenediaminetetraacetic acid 
ER: Endoplasmic reticulum 
FFI: Fatal familial insomnia 
GFP: Green fluorescent protein 
GPI: Glycosyl-phosphatidylinositol  
GSS: Gerstmann-Sträussler-Scheinker syndrome 
HD: Hydrophobic domain 
HRP: Horseradish peroxidase 
IP: Immunoprecipitation 
MEM: Minimum essential medium 
NMR: Nuclear magnetic resonance spectroscopy 
OR: Octa repeat 
ORF: Open reading frame 
PAGE: Polyacrylamide gel electrophoresis 
PBS: Phosphate buffered saline 
5 
 
PCR: Polymerase chain reaction 
PK: Proteinase K 
PNGase F: Peptide: N-glycosidase F 
PrP: Prion protein 
PrP
C
: Cellular prion protein 
PrP
Sc
: Scrapie prion protein 
SDS: Sodium dodecyl sulfate 
Sho: Shadoo 
SOD: Superoxide dismutase 
Tris: Tris(hydroxymethyl)aminomethane 
Triton X-100: t-octylphenoxypolyethoxyethanol 
TSE: Transmissible spongiform encephalopathies 
WT: Wild type 
 
 
 
 
 
 
 
 
 
6 
 
List of figures  
Figure 1. Structural features and biochemical properties of the cellular prion protein…...….10 
Figure 2. Schematic representation of the domain architecture of PrP family members…….12 
Figure 3. PrP
C
 internalization Pathways……………………………………………………...15 
Figure 4. Models for the conformational conversion of PrP
C
 into PrP
Sc…………………….18 
Figure 5. Possible pathways of PrP
Sc
 formation...…………………………………………...19 
Figure 6. Immunoblotting performed to verify expression levels of PrP in the ZW 13–2 and 
Zpl 2–1 cell lines………………………………………………………………………...........33 
Figure 7.  Immunocytochemistry verification of prion protein expression in ZW 13–2 and Zpl    
2–1 cells………………………………………………………………………………………34 
Figure 8. Sensitivity to transition metal-induced toxicity of ZW 13–2 and Zpl 2–1 cells…..37 
Figure 9. Morphological appearance of ZW 13-2 and Zpl 2-1 with Cu
2+…………………..38 
Figure 10. Morphological appearance of ZW 13-2 and Zpl 2-1 with Zn
2+…………………..39 
Figure 11. Morphological appearance of ZW 13-2 and Zpl 2-1 with Mn
2+………………….39 
Figure 12. Morphological appearance of ZW 13-2 and Zpl 2-1 with Co
2+………………….39 
Figure 13. Western blotting performed to verify expression levels of PrP in the generated 
stable Zpl 2-1-vector and Zpl 2-1-PrP cell lines……………………………………………...41 
Figure 14. Immunocytochemistry performed to verify prion protein expression in Zpl 2-1- 
PrP and Zpl 2-1-vector cells…………………………………………………………………42 
Figure 15. The percentage of PrP expressing cells in Zpl 2-1- PrP and Zpl 2-1-vector cells..43 
Figure 16. The expression of PrP in ZW 13–2 and Zpl 2-1-PrP stable cell………………….43 
Figure 17. Relative expressions of PrP from ZW 13–2 and Zpl 2-1-PrP cell lines………….44 
Figure 18. The effect of the presence of PrP
C
 on the susceptibility of cells to transition metal-
induced toxicity……………………………………………………………………………….47 
7 
 
Figure 19. Effect of PrP
C
 expression on the susceptibility of cells to Cu
2+
, Zn
2+
, Mn
2+
 and 
Co
2+ 
induced toxicity………………………………………………………………………….51 
Figure 20. Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Cu
2+………..52 
Figure 21. Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Zn
2+………..52 
Figure 22. Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Mn
2+……….53 
Figure 23. Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Co
2+………..53 
Figure 24. The effect of the presence of PrP
C
 on Cu
2+ 
transition metal induced cell death….55 
Figure 25. The effect of the presence of PrP
C
 on Zn
2+ 
transition metal induced cell death….57 
Figure 26. The effect of the presence of PrP
C
 on Mn
2+ 
transition metal induced cell death…58 
Figure 27. The effect of the presence of PrP
C
 on Co
2+
 transition metal induced cell death…59 
Figure 28. Prion protein expression levels in stable SH-SY5Y-vector and SH-SY5Y-PrP cell 
lines…………………………………………………………………………………………...62 
Figure 29. Effect of PrP
C
 expression on resistance to transition metal-induced toxicity…….65 
  
8 
 
1.  Introduction 
Spongiform degeneration and neuronal loss are characteristic histopathological 
hallmarks found in the brains of individuals suffering from transmissible spongiform 
encephalopathy’s (TSE) or prion diseases. Prion diseases are a family of rare and fatal 
neurodegenerative disorders that affect humans and many other mammals. They include 
Creutzfeldt-Jacob disease (CJD), Gerstmann Straussler syndrome (GSS), Familial Insomnia 
(FFI) and Kuru in humans,  Bovine spongiform encephalopathy (BSE) in cattle,  Chronic 
wasting disease (CWD) in deer and elk and scrapie in sheep (Aguzzi et al., 2008a; Collinge, 
2001; Prusiner, 1996, 1998a, 1998b). Human forms of TSE’s can be classified into three 
epidemiological categories, which count for different percentages of the observed cases: 
infectious (5%), sporadic (80%), and inherited (15%) (McKintosh et al., 2003).  
Prion diseases or TSEs are characterized by the deposition of an abnormal, protease 
resistant, infectious pathogenic “scrapie” isoform (PrPSc)  of the cellular prion protein (PrPC) 
in brain and in other tissues  (Meyer et al., 1986). Apart of TSEs, accumulation of protein 
aggregates, mostly fibrillar, accompanying the breakdown of normal tissue morphology 
seems to be a common phenomenon in many diagnosed neurodegenerative diseases. For 
example, Alzheimer’s disease (AD) is associated with the formation of β- amyloidal (Aβ, 
amyloid β) plaques formed by the aggregation of the amyloid precursor protein (APP) 
(Selkoe, 1991). It has been observed that an increase in intracellular tau and phosphorylated 
tau leading to the breakdown of microtubules could also be a disease mechanism associated 
with AD (LaFerla et al., 2007). Parkinson’s disease (PD) is associated with the formation of 
Lewy bodies produced by α-synuclein (Jellinger, 2012). Finally, Huntington’s (Htn) disease is 
caused by a mutation in the huntingtin gene (HTT) which leads to the production of fibrillar 
Htn plaques (Labbadia and Morimoto, 2013)(Aguzzi and Lakkaraju, 2015). The difference 
between TSE’s compared to other neurodegenerative diseases is that they can be transmitted 
9 
 
between hosts, whereas none of the other mentioned diseases have currently demonstrated any 
host to host transmission. Although all these diseases are associated with abnormal protein 
aggregation, it is generally not clear which aggregated state is responsible for the cell death 
(reviewed by Caughey and Lansbury, 2003). Growing evidence suggests the possibility of 
smaller size oligomers being responsible for cell damage and death, while larger fibrils may 
be more inert and even neuroprotective (Caughey and Lansbury, 2003). In case of TSEs 
additional challenge is to explain transmissibility, where the aggregated state of the infectious 
form of the prion protein may differ from the neurotoxic species (Caughey and Lansbury, 
2003). Despite the wide-ranging neuropathological studies into prion diseases, neither the 
mechanism by which PrP
Sc
 causes neuronal dysfunction nor the normal function of PrP
C
 is 
well defined. Although several functions have been recommended for the cellular isoform, 
PrP
C
, there is no consensus upon its role or upon whether which of these functions would be 
primarily associated with prion disease pathogenesis or prion replication. 
 
1.1 The prion protein   
1.1.1 Prion protein’s structure 
The normal cellular isoform of the prion protein, PrP
C
, is a highly conserved, 
approximately 250 amino acid containing glycoprotein that is widely expressed in the body: 
predominantly in neurons and glia of the CNS and can also be found in several peripheral 
tissues, and leukocytes (Aguzzi and Polymenidou, 2004; Dodelet and Cashman, 1998). In 
humans, PrP
C
 is encoded by a single exon of the PRNP gene located on the short arm of 
chromosome 20 (20p). PrP
C
 possesses two N-glycosylation sites and is GPI-anchored to the 
outer leaflet of the plasma membrane (Stahl et al., 1987). The structural features of the protein 
are well summarized by Figure 1 ((Aguzzi et al., 2008b). 
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Figure 1: Structural features and biochemical properties of the cellular prion protein. 
(A) Scheme of the primary structure of the cellular prion protein and its posttranslational 
modifications. A secretory signal peptide resides at the extreme N terminus. The numbers 
describe the positions of the respective amino acids. The proteinase K (PK)-resistant core of 
PrP
Sc
 is depicted in gray; the approximate cutting site of PK within PrP
Sc
 is indicated by 
arrows. CC (pink), charged cluster; HC (green), hydrophobic core; S-S, single disulfide 
bridge; MA, membrane anchor region; GPI, glycosylphosphatidylinositol; CHO, facultative 
glycosylation sites; NMR nuclear magnetic resonance. (B) Tertiary structure of the cellular 
prion protein, as figured out from NMR spectroscopy, inserted into a lipid bilayer, including 
the unstructured N-terminal tail (gray) and the GPI anchor. The α-helices are indicated in red; 
the antiparallel β-sheets are shown in turquoise. Sugar residues are shown as colored small 
circles. (adapted from (Aguzzi et al., 2008b)) 
 
The biosynthesis pathway of the prion protein is similar to that of other membrane and 
secreted proteins. PrP
C
 is synthesized at the rough endoplasmic reticulum (ER) during which 
it is subjected to post-translational modifications, including cleavage of the N-terminal signal 
peptide (Figure 1a) and attachment of the GPI anchor following the cleavage of the C-
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terminal signal peptide. In the ER the protein is properly folded, including the formation of a 
single intramolecular di-sulphide bond, before it is transported to the Golgi system. In Golgi, 
two N-glycosylation reactions may optionally occur, where complex oligosaccharides are 
attached to the two Asn residues in the loop formed between the two Cys residues 
participating in the di-sulphide bond  (Haraguchi et al., 1989).   As a consequence, when the 
protein is transported from the Golgi to the outer leaflet of the plasma membrane PrP
C
 can 
exist in unglycosylated, monoglycosylated, and diglycosylated forms (Westergard et al., 
2007). Structurally (Figure 1b), the C-terminal domain of PrP
C
 is folded largely into α-helices 
stabilized by a single di-sulphide bond and nuclear magnetic resonance (NMR) shows it exists 
in a monomeric state (Riek et al., 1996). Studies of the crystal structure of the C-terminal half 
of PrP revealed that it contains three α-helices and a short anti-parallel β-sheet (Eghiaian et 
al., 2004; Haire et al., 2004; Knaus et al., 2001). Contrary, the N-terminal half is disordered. 
The N-terminal domain of PrP consists of positively charged amino acid sequences and an 
octapeptide repeat (OR) sequence (Figure 1a) , which can bind Cu
2+
, Zn
2+
 and other transition 
metal ions suggesting a possible role of it in ion regulation/signaling (Hosszu et al., 1999; 
Jackson et al., 2001a; Riek et al., 1998). The middle region between residues 106–126, 
constitutes a highly conserved hydrophobic domain (HD) rich in alanine and valine. 
 
1.1.2 PRNP and its paralogs 
The human PRN gene locus contains three genes: PRNP, PRND, and a novel gene 
SPRN (Makrinou et al., 2002). The cellular prion protein (PrP
C
) is encoded by the PRNP gene 
as a single copy.  
First prion-related gene is Doppel (Dpl) or “downstream prion protein-like gene,” 
(Moore et al., 1999). The gene encoding Dpl, labeled PRND, is located at the same locus as 
the PRNP gene. It has been found that Dpl shares several structural and biochemical features 
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with PrP
C
 (Silverman et al., 2000). Dpl shows 25% primary sequence similarity with the C-
terminus of PrP
C
 (Figure 2) and both proteins are structurally similar, which has been revealed 
by NMR studies (Mo et al., 2001).  
 
  
Figure 2: Schematic representation of the domain architecture of PrP family members. 
Doppel and PrP
C
 have structured C-terminal domains consisting of 3 α-helices (in red) and 2 
short β-strands (in purple) as well as positively-charged N-terminal regions. Disulfide bridges 
are indicated above the proteins (–S–S–) and N-glycosylation sites (CHO) are denoted below 
the proteins. Repetitive regions are found in both PrP
C
 (green) and Shadoo (dark red) with the 
former possessing octarepeats binding copper and the latter possessing tetrarepeats rich in 
arginine and glycine residues. A conserved hydrophobic domain is also illustrated in PrP
C
 and 
Shadoo (yellow). N-terminal signal sequences (white) are cleaved in all of them. (adapted 
from (Ciric and Rezaei, 2015)). 
 
Similarly to PrP
C
, Dpl also has two N-glycosylation sites and a 
glycosylphosphatidylinositol (GPI) anchor, which results in a similar localization in the outer 
surface of the plasma membrane. Since Dpl was discovered, much attention has been devoted 
to Dpl research. In particular, the study of Dpl-induced cerebellar neurodegeneration, that has 
demonstrated the importance of the N-terminal domain of PrP
C
 in neuroprotection. In fact, 
expression of N-terminally truncated form of PrP [PrP(Δ32–121) or PrP(Δ32–134)] 
in Prnp
0/0
 mice (Flechsig et al., 2003) leads to ataxia and Purkinje cell loss in the same 
fashion as Dpl ectopic expression (Anderson et al., 2004). The cytotoxic effects of ΔPrP 
(Δ32–121 or Δ32–134)  and of Dpl are rectified by full-length PrP (Cui et al., 2003; Nishida 
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et al., 1999; Yamaguchi et al., 2004), suggesting common molecular mechanisms for the 
truncated forms of PrP and Dpl, most likely of interfering in some cellular pathways essential 
for cell survival, in which the full-length PrP is involved as with an anti-apoptotic activity 
(Shmerling et al., 1998; Watts and Westaway, 2007).   
A nascent protein product encoded by SPRN ORF is another member of PrP family 
(Figure 2). The new prion-related gene outside of PRN locus was discovered by Premzl in 
2003 during an exploration for potential homologs of PrP in the NCBI non-redundant protein 
database. The SPRN gene, encoding for a protein designated as shadow of prion protein 
(Shadoo, Sho), is found to be highly conserved from fish to mammals (Premzl et al., 2003). 
As the name suggests, Sho, the shadow protein of PrP, has several characteristic features that 
resemble that of  PrP
C
. Structurally there are two features which exists in both Shadoo and the 
PrP’s natively unstructured N-terminus: i) a series of positively charged tandem repeats with 
short sequences ii) a hydrophobic domain (HD) (Figure 2). Also, like the other two members, 
Sho carries a GPI anchor signal sequences and one or two N-glycosylation sites which were 
experimentally confirmed on the endogenous protein in brain homogenates (Miesbauer et al., 
2006; Watts et al., 2007). Besides these structural similarities, several other correlations have 
been identified. Both proteins are mainly expressed in the brain, with both overlapping and 
differential expression areas: Sho expression overlaps PrP
C
, but is low in cerebellar granular 
neurons (CGNs) containing PrP
C
 and high in PrP
C
-deficient dendritic processes (Lampo et al., 
2007; Premzl et al., 2003; Watts et al., 2007). Importantly, the expression levels between 
PRNP and SPRN mRNA showed a highly significant positive correlation in sheep cerebrum 
and cerebellum tissues, suggesting a co-regulation of the genes in these tissues (Lampo et al., 
2009). Specially, while the infectious particle PrP
Sc
 accumulated, both PrP
Sc
-infected animals 
and infected neuroblastoma cells showed extremely decreased levels of Sho protein (Watts et 
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al., 2007, 2011; Westaway et al., 2011). Taking these findings together, Sho seems to show a 
functional link with PrP and could take part in the process of prion diseases. 
 
1.1.3 Prion protein localization 
In order to identify the intracellular compartments and the mechanisms that underlie 
the formation of prion disease, it is essential to know  the precise cellular localizations of PrP
C
 
and PrP
Sc
. As a natively GPI-anchored protein, the major sites of PrP
C
 localization include: 
the ER, Golgi, plasma membrane, exosomes, and endolysosomes, however, , PrP was also 
reported in the cytosol and the nucleus as a result of misprocessing by the ER (Fevrier et al., 
2004; Magalhães et al., 2002; Mangé et al., 2004; Mironov et al., 2003; Sarnataro et al., 2002, 
2004). Currently, there is a substantial gap in our understanding of PrP
Sc
 localization as there 
are no specific antibodies for PrP
Sc
. However, studies suggest a wide cellular distribution, in 
particular at the plasma membrane and in the endolysosomal compartment (Arnold et al., 
1995; Caughey and Raymond, 1991; Jeffrey et al., 1992). Under certain situations, it have 
been reported that PrP
Sc
-like structures will accumulate in the cytosol and there is also 
evidence for cytosolic PrP
Sc
-containing aggresomes in prion-infected cells following the 
proteasome inhibition (Kristiansen et al., 2005; Ma and Lindquist, 2002). 
 
1.1.4 Trafficking: PrP
C
 endocytosis pathways  
Following synthesis in the ER, PrP
C
  is trafficked via the Golgi to the cell surface, 
where it constitutively cycles between the plasma membrane and early endosomes (Shyng et 
al., 1993). Several mechanisms have been proposed to explain PrP
C
 internalization (Campana 
et al., 2005) such as clathrin-mediated endocytosis, caveolin-associated endocytosis and raft 
dependent endocytosis (Figure 3). As the main route, PrP
C
 has been shown to recycle from the 
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cell surface to endosomes via clathrin-coated pits (Shyng et al., 1994; Sunyach, 2003; Taylor 
et al., 2005).  
 
 
 
Figure 3: PrP
C
 internalization Pathways.  (i) A main pathway of PrP
C
 internalization in 
neuronal cells appears to depend on clathrin-mediated endocytosis. (ii) Caveolin-associated 
endocytosis and trafficking have been implicated in PrP
C
 internalization in Chinese hamster 
ovary and glial cells.  Rab5-positive endosomes and Rab4 involving recycling endosomes 
have also been implicated in the PrP
C
 endocytic transport. (iii) Finally, non-clathrin and non-
caveolin but raft dependent endocytosis has been proposed to participate in the internalisation 
and conversion of prion protein. (adapted from (Campana et al., 2005)) 
 
It had been shown that the basic amino acid motif in the N-terminal region of PrP
C
 is 
required for its localization to clathrin-coated pits and the subsequent internalization of it (Lee 
et al., 2001a; Sunyach, 2003). These findings suggest that the N-terminal region of PrP
C
 may 
be binding to a transmembrane protein containing a localization signal for coated pits. 
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Another putative mechanism of internalization in various cell models has been proposed, 
which states that PrP
C
 clusters in caveolae or caveolae-like domains (Kaneko et al., 1997; Vey 
et al., 1996). Further, prion protein internalization mechanism involves lipid rafts. GPI-
anchored prion protein needs to translocate out from its lipid rafts into non-raft regions of the 
membrane to internalize through clathrin-coated pits. Indeed, Sunyach et al. confirmed that 
using primary cultures of neurons as well as neuroblastoma N2a cells, PrP
C
 translocates out of 
the lipid rafts (detergent-insoluble) into non-raft regions of the membrane, following which it 
enters clathrin-coated pits for endocytosis and cycles back to the cell surface via perinuclear 
sorting compartments (Sunyach, 2003). 
Several proteins have been suggested to bind and act as endocytic partners for 
PrP
C
(Linden et al., 2008; Morris et al., 2006). For example, the NH2-KKRPKPGGW- amino 
acid residues of the N-terminal domain of PrP
C 
have been identified as a major heparin 
sulphate binding site of PrP
C
 (Pan et al., 2002)(Warner et al., 2002). Recently, it has been 
shown that LRP1 binds to PrP
C
 to facilitate its trafficking to the neuronal surface and that 
LRP1 associates with endogenous PrP
C
 on the neuronal cell surface to internalize it (Parkyn et 
al., 2008). Cu
2+
 has also been demonstrated to draw PrP
C
 out of its rafts prior to its 
endocytosis in SH-SY5Y cells  and more recently it was shown that in the same cell model, 
LRP1 is required for Cu
2+
-dependent endocytosis of exogenous PrP
C
 (Taylor and Hooper, 
2007; Taylor et al., 2005).  
 
1.2. Conformational transition from PrP
C
 to PrP
Sc
   
 It is widely accepted that the conformational transition of the native and 
predominantly α-helical PrPC to the β-sheet containing pathogenic isoform PrPSc, results in 
the extracellular accumulation of PrP
Sc
 aggregates. The exact mechanism for the 
conformational conversion is not yet known but several theories have been proposed.  
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According to the widely accepted “protein only” hypothesis, two mechanisms have 
been proposed to explain the conformational conversion of PrP
C
 into PrP
Sc
 (Aguzzi and 
Calella, 2009). (i) The “template-directed refolding” hypothesis, which postulates an 
interaction between PrP
Sc
 and endogenous PrP
C
 to induce the conformational conversion 
(Figure 4A) (Prusiner, 1991); and (ii) a “seeded nucleation” hypothesis suggests that PrPSc 
exists in equilibrium with PrP
C
 (Figure 4B) (Jarrett and Lansbury, 1993). According to this 
“seeded nucleation” hypothesis, the infectious agent would consist of a highly ordered 
aggregate state of PrP
Sc
 and it would be an essential property of infectivity. Monomeric PrP
Sc
 
might not exist in isolation, but in any case, would be harmless, while it might be prone to 
incorporation into nascent PrP
Sc
 aggregates (Aguzzi and Calella, 2009). 
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Figure 4: Models for the conformational conversion of PrP
C
 into PrP
Sc
. (A) the 
“template-directed refolding” hypothesis postulates an interaction between exogenously 
introduced PrP
Sc
 and endogenous PrP
C
, which is induced to transform itself into further 
PrPSc. A high-energy barrier may prevent spontaneous conversion of PrP
C
 into PrP
Sc
. (B) 
“seeded nucleation” hypothesis proposes that PrPC and PrPSc are in a reversible 
thermodynamic equilibrium. Only if several monomeric PrP
Sc
 molecules are mounted into a 
highly ordered seed, can further monomeric PrP
Sc
 be recruited and eventually aggregate to 
amyloid. (adapted from (Aguzzi and Calella, 2009)) 
 
The conversion of PrP
C
 to PrP
Sc
 has been proposed to take place along numerous pathways 
(Figure 5) (Campana et al., 2005).  
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Figure 5: Possible pathways of PrP
Sc
 formation. After its synthesis and ER quality control, 
PrP
C
 is transported through the Golgi apparatus to the cell surface, where it associates with 
rafts and is internalized by clathrin- and/or caveolin dependent mechanisms. (i) Blocking 
transport of PrP
C
 to the plasma membrane and rerouting it to lysosomes for degradation. (ii) 
Releasing nascent PrP
C
 from the cell surface prevents the formation of PrP
Sc
. (iii) A reduction 
in PrP
C
 internalization also decreases PrP
Sc 
formation. Both PrP isoforms are found in Rab5-
positive early endosomes, pass through late endosomes and are totally (PrP
C
) or partially 
(PrP
Sc
) degraded in acidic lysosomes. Moreover, part of the PrP
C
 pool is recycled back to the 
plasma membrane in a Rab4-dependent pathway, and both PrP
C
 and PrP
Sc
 are found 
associated with exosomal membranes in the extracellular medium of infected cells. (iv) The 
ER has been postulated to have a role in prion conversion by amplifying PrP
Sc
 formation after 
the Rab6a-dependent retrograde transport of PrP
C
. (adapted from (Campana et al., 2005)) 
 
Among them, first, studies suggest that PrP
C
 mutants, which are associated with 
familial forms of CJD, are retained by chaperones in the ER (Campana et al., 2006; Drisaldi et 
al., 2003), thereby indicating that, in inherited prion disease the conversion process could be 
occurring early in the biosynthesis of PrP
C
. Second, in the conversion process, as studies have 
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shown, direct surface contact is required for the transfer of infection in cell models of scrapie 
(Kanu et al., 2002). Third, when released from scrapie-infected cells, exosomes have been 
implicated to carry infection (Aguzzi and Lakkaraju, 2015; Fevrier et al., 2004) and fourth, in 
conversion of PrP
C
 to PrP
Sc
, endocytic pathway could be involved as per the evidences 
(Borchelt et al., 1992; Taraboulos et al., 1992). Furthermore, it is also possible that prions use 
lipid rafts to enter cells and to initiate and/or propagate the conversion of PrP
C
 to PrP
Sc
 
(Campana et al., 2005). Up to date there is no consensus on whether all, or which of these 
routes would be primary means of cellular conversion of PrP
C
(Aguzzi and Lakkaraju, 2015). 
 
1.3 Functions of PrP
C
  
The exact cellular functions of PrP
C
 are still unknown. However, in the last several 
years, various biological functions have been suggested, which includes copper metabolism, 
signal transduction, antioxidant activity, neurotransmitter metabolism, neurogenesis, immune 
cell activation, cell adhesion, and homeostasis of trace elements (Brown et al., 1997a, 1997b; 
Cashman et al., 1990; Graner et al., 2000; Kawahara et al., 2011; Lee et al., 1999; Mangé et 
al., 2002; Mouillet-Richard et al., 2000). 
 
1.3.1 PrP – metal relations 
The direct or indirect interactions of PrP with various transition metals has been 
implicated in both TSE and Alzheimer's, as being a contributing factor for triggering a 
neurodegenerative condition (Ayton et al., 2013; Rana et al., 2009; Solomon et al., 2012). 
Both in vivo and in vitro studies have demonstrated that PrP
C 
binds divalent cations (La 
Mendola and Rizzarelli, 2014). Experimental and molecular dynamics studies on recombinant 
PrP and PrP-derived peptides have indicated the existence of a number of potential binding 
sites for divalent metal ions. The most encountered site is the OR of PrP
C
 which can bind to 
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copper, zinc, manganese, nickel and iron; among which copper shows the highest binding 
affinity to the OR region (Jackson et al., 2001b; Pandey et al., 2010; Russo et al., 2011; Singh 
et al., 2010; Stöckel et al., 1998). Majority of the earlier hypotheses about the normal cellular 
function of PrP
C
, addressed the protein as a Cu
2+
-binding protein (Brown et al., 1997c).  The 
structure and stability of the formed complexes between PrP and metals are highly dependent 
on pH and metal/ligand ratio (Miura et al., 2005; Di Natale et al., 2013; Viles et al., 1999). In 
the presence of sub-stoichiometric metal concentrations or acidic pH, the imidazole nitrogen 
atoms are the only true effective donor atoms for both copper and zinc. Macro-chelates are 
formed, in which up to four histidines bind to a single metal ion. Two additional copper 
coordinating sites have also been identified at His-96 and His-111 in human PrP
C
.
 
At neutral 
or basic pH and in the presence of concentrations of copper (at least equimolar with respect to 
the peptide), all histidines can behave as independent coordination sites and PrP
C
 can bind up 
to six Cu
2+
 ions in vivo (Brown et al., 1997d) as reviewed recently (Kozlowski et al., 2013). In 
this case, the amide nitrogen atoms come predominantly from the neighboring glycines. Zn
2+
 
is not able to displace amide protons and thus forms less stable complex in respect to Cu
2+
.  
Although PrP
C
 has an apparent affinity toward several transition metals, it is much less 
clear that which of these interactions are attributable to a physiological activity of PrP
C
.  This 
has prompted a number of in vitro and in vivo studies to investigate this relation (Li et al., 
2004; Rana et al., 2009; Waggoner et al., 2000). Transition metal-PrP
C
 interactions might 
have an impact on PrP
C
 biology by internalization and shedding of PrP
C
 that were reported to 
occur in response to transition metal stimuli (Brown and Harris, 2003; Parkin et al., 2004; 
Pauly and Harris, 1998).   
Cu
2+
 and Zn
2+
 induced rapid endocytosis of PrP
C
 was a major breakthrough discovery, 
thus linking metal binding to a physiological response (Pauly and Harris, 1998; Watt and 
Hooper, 2003). Accordingly, PrP
C
 is thought to possess a Cu
2+
-dependent enzyme function, 
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specifically to participate in Cu
2+
 homeostasis or function as an antioxidant. The prion protein 
shows evidence of Zn
2+
 binding in solution, with an affinity that is two to three orders of 
magnitude lower than that of Cu
2+ 
(Pan et al., 1992). It has been shown that concomitant with 
conformational change to PrP
Sc
 form, neuronal cells undergo imbalance in 
Zn
2+
 homeostasis (Watt and Hooper, 2003). Linking PrP–Zn2+ interaction with endocytosis 
(Watt et al., 2012), a PrP
C
 → PrPSc conversion would be expected to alter the level of Zn2+ in 
the infected brain tissues. However, there are contrasting reports in this respect.  
The report of other metal ions, especially Mn
2+
 interaction with prion protein came 
from the studies of Brown et al. (Brown et al., 2000). In their work, they demonstrated that 
Mn
2+
 can actually replace Cu
2+
 in PrP
C
 in its full length form and display the same SOD 
activity as the Cu
2+
-bound form of the protein. Further, when Mn
2+ 
bound to PrP
C
 rendered 
the protein protease resistant and assumed structures similar to those of PrP
Sc
, phenomenon 
shown for the first time. It has also been observed that the replacement of bound Cu
2+
 by 
Mn
2+
 significantly increases the β-sheet content of PrPC, thereby leading to fibril 
formation (Brown et al., 2000). This has been proposed to be principally due to differences in 
the interactions of Mn
2+
 and Cu
2+
 with PrP. Some studies demonstrated that cellular prion 
protein serves as a protective agent against Mn
2+
-induced oxidative stress (Choi et al., 2007). 
Fe
2+
 regulation has been shown to be disturbed in scrapie-infected cells, leading to 
higher Fe
2+
 levels which cause increased formation of reactive oxygen species and cell death. 
These findings suggest that, infection by scrapie is linked to the changes in 
Fe
2+
 homeostasis (Fernaeus et al., 2005; Kim et al., 2000). Significant evidence also exists for 
the Fe
2+
-binding property of PrP
C
 (Fernaeus et al., 2005). Scrapie infected mouse-brain 
homogenates as well as CJD infected human brain homogenates show four to six-fold more 
Fe
2+
 as compared to age-matched controls. The binding affinities and dissociation constants of 
Fe
2+
 to prion protein are yet to be established. Other divalent cations such as Ni
2+
, Cd
2+
 and 
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Ca
2+
 have also been known to show weak binding to prion protein (Jackson et al., 2001b), 
although the effects of such binding to the physiological functions of PrP
C
 or to the 
pathogenesis of prion diseases are yet to be investigated in detail.  
The interaction of the cellular prion protein with different divalent metal cations is 
found to have several common features: 1) Involvement in oxidative stress mechanisms 2) 
Common binding sites in the octarepeat region 3) Alteration in the metal levels inside the 
cells 4) Linkage between PrP
C
 expression and extracellular metal concentrations 5) 
Conformational effects, such as conversion to protease and detergent resistant forms 6) 
Altered interactions with PrP
Sc
 infected forms. 
1.3.2 Role of divalent cations in the pathogenesis of prion diseases 
Prion diseases caused by the accumulation of PrP
Sc
 isoform mainly affect the brain 
regions that co-ordinate motor function including the cerebellum, thalamus, cerebral cortex, 
and the basal ganglia. Most in vivo studies of prion disease have also shown that there is an 
interrelationship between PrP
Sc
 formation and altered levels of several divalent metal cations 
including Cu
2+
, Zn
2+
, Mn
2+
 and Fe
2+
, thereby suggesting a possible role for these metals in the 
pathogenesis of prion diseases. 
  Cu
2+
 can induce conversion of PrP
C
 to a PK-resistant species, having a conformation 
distinct from PrP
Sc
  reported by Qin et al. and Quaglio et al. (Qin et al., 2000; Quaglio et al., 
2001). Furthermore, from the protein renaturation experiments on GdnHCl-denatured PrP
Sc
, it 
was found that PK-resistant infectious prions regeneration was  enhanced by the presence of 
Cu
2+
(McKenzie et al., 1998). Also, acidic-pH mediated conversion of ovine PrP to a PK-
resistant β-sheet rich structure was shown to be modulated by Cu2+ (Liu et al., 2008). In a 
subsequent paper, Wong et al. (Wong et al., 2001a) demonstrated that not only Cu
2+
 but other 
metal ions such as Mn
2+
 and Zn
2+
 also display pivotal role in prion pathogenesis.  
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PrP
Sc
 infected mice showed a higher Mn
2+
 content in brain, muscles and blood 
compared to normal mice (Thackray et al., 2002). It has been known that in the presence of 
Mn
2+
, recombinant PrP
C
 converted into a proteinase-K-resistant non-pathogenic, abnormal 
isoforms of PrP
Sc
. Basu and coworkers reported that PrP
C
 on the surface of human 
neuroblastoma cells binds to an inorganic source of redox Fe
2+
 and induces conversion of 
PrP
C
  into a PrP
Sc
-like form (Basu et al., 2007). This isoform shows similar characteristics of 
the scrapie form such as typical proteinase-K resistance and detergent insolubility. These 
results indicate a strong correlation between prion disease pathogenesis and Fe
2+
 levels, which 
could be linked to the conversion of PrP
C
 into a PrP
Sc
-like form. However, the exact 
mechanism of such an interaction remains unknown. 
 
1.3.3 PrP functions as antioxidant  
Free transition metal ions are especially highly effective in generating reactive oxygen 
species (ROS) that can induce lipid peroxidation and protein oxidation, leading to cellular 
damage (Berlett and Stadtman, 1997; Lee et al., 2012). Many reports showed a protective role 
of PrP
C
 against cellular stresses, especially against  oxidative damage, which is perhaps one of 
the most widely accepted functions of PrP
C
 (Brown et al., 1997b, 1997d; Holada et al., 2002; 
Klamt et al., 2001; Rachidi et al., 2003a; White et al., 1999; Wong et al., 2001b). Remarkably, 
the loss of antioxidant defense was suggested to play a major role in scrapie-infected cells  
and prion diseases (Arlt et al., 2002; Guentchev et al., 2000, 2002; Milhavet et al., 2000; 
Wong et al., 2001c). Regarding the mechanisms of these protective effects of PrP
C
, it was 
shown that cultured cells derived from Prnp
−/−
 mice were more sensitive to oxidative damage 
and exhibited reduced superoxide dismutase (SOD) activity when compared with WT (Brown 
et al., 1997b). Furthermore, recombinant PrP
C
 refolded in the presence of Cu
2+
 was reported 
to have SOD activity (Brown et al., 1999) although other authors found neither decreased 
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SOD activity in Prnp
−/−
 mice nor SOD activity with recombinant PrP
C
 (Jones et al., 2005; 
Sakudo et al., 2003; Waggoner et al., 2000). In addition, experiments using genetically 
modified mice, as well as cross between PrP
C
 overexpressing and SOD-deficient mice argue 
against such a role for PrP
C
 in vivo (Hutter et al., 2003).  
Alternatively, it is possible that the binding of Cu
2+
 or Zn
2+
 to PrP
C
 that induces its 
endocytosis, is a signal for triggering antioxidative defense (Brown and Besinger, 1998; 
Brown et al., 1997b; Vassallo and Herms, 2003) even though non-oxidative mechanisms are 
considered (Haigh and Brown, 2006). Nevertheless, the mechanism is not clear. A protective 
effect for PrP
C
 or its fragments in metal-induced toxicity has been reported in few studies by 
using various model systems (Choi et al., 2007; Haigh and Brown, 2006; Rachidi et al., 2009).   
The aim of the presented studies in the current thesis is to examine the role of PrP in 
condition of metal stress  induced by various concentrations of Cu
2+
, Zn
2+
, Mn
2+
, and 
Co
2+
, using the hippocampus-derived mouse neuronal cells, Zpl (Prnp
-/-
) and ZW (Prnp
+/+
), 
and the SH-SY5Y human neuroblastoma cells as model systems. 
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2. Main objectives of the thesis  
Prion protein has been reported to have a protective role against certain transition 
metals induced toxicities in cell culture model systems (Choi et al., 2007; Haigh and Brown, 
2006; Rachidi et al., 2009), however, the data are not absolutely univocal in the different 
systems used. The hippocampus-derived, Prnp
-/-
 ablated, Zpl 2-1 cells have been shown to be 
more vulnerable to serum deprivation and oxidative damage induced by H2O2 than its PrP-
expressing counterpart, ZW cells, derived from the wild type mice (Kim et al., 2004; Oh et 
al., 2008, 2012), furthermore reintroduction of PrP restored the viability of Zpl cells in this 
context. Thus, this model system seems to be relevant for assessing the effect of PrP
C
 on 
metal-induced toxicity as well. The main objective of my Ph.D. thesis was to test whether PrP 
has any general protective role against metal-induced toxicity in this system, using four 
different metals. The specific aims of my Ph.D. thesis were to answer the following questions: 
 
1) Does the PrP lacking Zpl 2-1 cells are more susceptible to Cu2+, Zn2+, Mn2+ and Co2+ 
induced toxicities than the control ZW cell line?  
2) Does PrP expression generated in Zpl cells confer any elevated resistance to the cells 
against metal-induced toxicity? 
3) Would the PrP expression generated SH-SY5Y cells, as a different model system, 
confer increased resistance to the cells against Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 metal-
induced toxicities?  
 To address the above questions we chose methods that report on the general health of 
the cells, rather than looking at a specific pathway involved: such as alamarBlue viability 
assay, propidium iodide-based dye exclusion assay and morphological examination of the 
cells. Also, we extended the studies to four different metals, which were applied in various 
concentrations:  Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
.  
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3. Materials and Methods 
3.1 Reagents and antibodies 
All chemicals used were from Sigma-Aldrich unless stated otherwise.  
AlamarBlue cell viability reagent was from Life Technologies (DAL1100). Protease Inhibitor 
Cocktail and Phenylmethanesulfonyl fluoride (PMSF) were from Sigma-Aldrich (P2714 and 
P7626, respectively). PNGase F was from New England Biolabs (P0704), TurboFect 
Transfection Reagent  was from Thermo Scientific (R0531), RC DC Protein Assay kit was 
from Bio-Rad (500–0121), Copper(II) sulfate pentahydrate, Zinc (II) sulfate heptahydrate and 
cobalt chloride (II) hexahydrate were from Molar Chemicals Kft, MnCl2 was from Sigma-
Aldrich (M8054). 
Anti-Prion Protein Monoclonal Antibody was from Spi-Bio (Clone SAF 32; A03202), 
Anti-Mouse IgG (Fab specific)–Peroxidase antibody and β-Actin antibody were from Sigma-
Aldrich (A3682 and A5316, respectively), Alexa Fluor 568 Anti-Mouse IgG (H+L) was from 
Life Technologies (A11004).  
All cell culture reagents were from Life Technologies/Gibco; high glucose Dulbecco's 
Modified Eagle's medium (DMEM) (41966), DMEM/F-12 (31331), Fetal Bovine Serum 
(FBS) (10500), Penicillin Streptomycin (15070), GlutaMAX (35050).  
 
3.2 Cell culturing, transfection and generation of stable cell lines 
Neuronal cell lines ZW 13-2 and Zpl 2-1, were established from the hippocampus of 
ICR (Prnp
+/+
) and Zurich I Prnp
−/−
 mice, respectively, by Kim and coworkers [63]. Zpl 2-
1and SH-SY5Y cell lines stably expressing mouse PrP and GFP (Zpl 2-1-PrP and SH-SY5Y-
PrP) or GFP and puromycin resistance gene (Zpl 2-1-vector and SH-SY5Y-vector) were 
produced as follows. Briefly, 1x10
5 
cells/well were seeded on a 6-well plate and transfected 
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using TurboFect transfection reagent, according to manufacturer's protocol. The following 
plasmids were introduced to the cells: A Sleeping Beauty plasmid (pSB), containing two 
expression cassettes between transposon arms, one coding the Enhanced Green Fluorescent 
Protein (EGFP) driven by CMV promoter, and the other coding either wild type mouse prion 
protein (PrP) or a puromycin resistance gene driven by a CAG promoter. The second plasmid 
(SBx100) was coding for an active transposase enzyme to catalyze the linked integration of 
the two expression cassettes from the pSB plasmid. GFP positive cells were sorted 3 and 14 
days post-transfection using a FACS Aria fluorescence-activated cell sorter. The cells were 
amplified and frost at about 35 post-transfection. The expression and localization of GFP and 
PrP were confirmed by western blotting and immunocytochemistry. ZW and Zpl cells were 
maintained in DMEM supplemented with 10% FBS, 1% GlutaMAX and 1% penicillin-
streptomycin at 37 °C under 5% CO2. SH-SY5Y cells were maintained in DMEM/F-12 
supplemented with 10% FBS, 1% GlutaMAX and 1% penicillin-streptomycin at 37 °C under 
5% CO2 
 
3.3 Western blot analysis 
One 10 cm Petri dish of confluent cultured cells were washed twice with ice-cold 
phosphate buffered saline (PBS) and scraped in a 1 ml volume of PBS. Cells were pelleted by 
centrifugation at 500 ×g and 4 °C for 5 min. The supernatant was removed, and the pelleted 
cells were resuspended and lysed in cold lysis buffer (50 mM Tris–HCl pH 7.4, 1 mM EDTA, 
150 mM NaCl, 1% Triton X-100) supplemented with 1 mM phenylmethyl sulfonyl fluoride 
and protease inhibitor cocktail, and solubilization for 30 min on ice. Lysed cells were 
centrifuged at 15000 ×g and 4 °C for 10 min to pellet and remove insoluble materials. Protein 
concentration of the soluble fraction was determined using RC-DC Protein Assay. For studies 
involving PNGase F digestion, each sample was treated with PNGase F as directed by the 
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manufacturer. Briefly, each sample of 20 µg protein was denatured at 100 °C for 10 minutes 
and incubated with and without of 1,500 units of PNGase F at 37 °C for 2 hours. Samples 
were then analyzed by Western blot as follows. Equal amounts of total proteins, typically 10 
g were loaded on 12% polyacrylamide gels, separated by SDS-PAGE and transferred to 
methanol-activated Hybond-P polyvinylidene difluoride membrane (Millipore). The 
membrane was blocked by 5% nonfat dry milk in PBS containing 0.05% Tween 20 (PBST) 
for 1 h at room temperature followed by an overnight incubation with primary antibody 
against PrP (1:3000), or β-actin (1:10,000). Blots were then incubated with horseradish 
peroxidase conjugated secondary antibody. The reactive protein bands were visualized on X-
ray films by Chemiluminescent substrate (Millipore) and were subsequently quantified by 
densitometry analysis of the gray-scale images of the scanned films using the ImageJ 
software. 
 
3.4 Immunocytochemistry 
Immunocytochemistry was used to determine the expression of PrP in the neuronal 
cell lines used. Cells were plated at ~0.5x10
5
 cells/ml onto 8-well chamber microscope slides 
(Nunc, Lab-Tek II). After 24 h of seeding, cells were washed with PBS and were fixed with 
fresh 4% paraformaldehyde (PFA) for 10 minutes at room temperature. PFA was removed by 
washing the cells with PBS. Samples were blocked by adding blocking solution (1% BSA in 
PBS) for 45 min at room temperature, and were incubated with anti PrP (SAF-32) primary 
antibody at 1:250 dilution in blocking solution, overnight at 4 °C. From each cell line one 
well was kept in blocking solution without applying the primary antibody, to serve as controls 
for estimating the background signal coming from unspecific binding of the secondary 
antibody. Next day cells were washed with blocking solution to remove primary antibody, 
followed by incubation with an anti-mouse Alexa Fluor 568 conjugated secondary antibody 
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used at 1:300 dilution in blocking solution for 1 h at 37 °C. Unbound antibodies were washed 
by PBS and cells were incubated in 100 ng/ml 4′,6-diamidino-2 phenylindole HCl (DAPI) for 
5 min to stain DNA. DAPI was washed out by PBS and cells were imaged in PBS by using a 
confocal laser scanning microscope Fluoview FV1000 (Olympus Life Science Europa GmbH, 
Hamburg, Germany). Microscope configuration was as follows: UPLSAPO 60X (oil, 
NA:1.35) objective, zooming factor of either 4 or 1, sampling speed 4 µs/pixel, line averaging 
2X , scanning mode sequential, unidirectional, excitation 405 nm (DAPI detection) and 543 
nm (with Alexa568 red fluorescence detection). Counting of the PrP positive cells of the 
transformant Zpl 2-1-PrP and Zpl 2-1-vector cells from the microscopy pictures was 
performed using five pictures recorded with 60X objective, no zooming, which equaled to 
populations of at least 250 cells. 
 
3.5 Metal ion treatment of cells 
When cells reached the desired confluency for a specific assay the media on top of the 
cells was supplemented with the indicated concentrations of either CuSO4, ZnSO4, CoCl2, or 
MnCl2. CuSO4 in all cases was administered as a 1:4 mol/mol ratio with glycine (Cu
2+
-Gly), 
which was pre-mixed fresh before the treatment. There was no any observable color change of 
the metal stock solution or metal supplemented media during the metal ion treatments, which 
would be indicative of a higher oxidation state of either cobalt or manganese. Treatments with 
metals were performed for 24 h duration before starting the assays.  
 
3.6 Cell viability assays and cell morphology 
Cell viability was determined by using alamarBlue cell viability reagent and a 
microplate reader Fluoroskan Ascent FL Microplate Fluorometer and Luminometer (Thermo 
Scientific). Briefly, cells were seeded into 96-well flat-bottomed plates to reach 40% 
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confluency by 24 h. The next day, the cells were either untreated (control) or treated with 
designated concentrations of Cu
2+
, Zn
2+
, Mn
2+
 or Co
2+
, respectively, for 24 h. The cell 
proliferation assay was performed according to the manufacturer’s instructions and 
fluorescence was measured by the microplate reader. At the indicated concentrations of the 
metal ions, morphological changes of the cells were also examined by using an Olympus 
CellR microscope and a 10X objective. 
 
3.7 Cell-death assays 
Cell-death was measured by propidium iodide (PI) exclusion assay. Briefly, cells were 
seeded into 6-well flat-bottomed plates to reach 40% confluency by 24 h. The next day, cells 
were either untreated (control) or treated with designated concentrations of Cu
2+
, Zn
2+
, Mn
2+
 
or Co
2+
 , respectively, for 24 h. Treated and untreated cells were collected, including dead 
floating cells in the medium, and were washed twice in PBS before re-suspension in 2 g/mL 
PI. Percentage of dead cells up-taking PI was measured by flow cytometry (BD FACSCalibur 
Flow Cytometer, BD Biosciences).  
 
3.8 Statistical analysis 
Statistical analysis was performed on data originating from N=3 to 5 independent 
experiments using Sigmaplot 12.5 software. The data are represented as the means ± standard 
deviation (S.D). For comparison between two samples, a two-tailed Student’s t-test was 
performed and values of p<0.05, p<0.01 and p<0.001 were taken as being statistically 
significant.  
 
 
32 
 
4. Results 
 
The prion protein’s role in a particular cellular process, including those that are 
concerned with metal-PrP interrelations in ex-vivo and in-vivo systems are generally studied 
by either genetically ablating (Büeler et al., 1992; Haigh and Brown, 2006; Kim et al., 2005; 
Kuwahara et al., 1999; Rossi et al., 2001; Sakaguchi et al., 1996) or siRNA silencing (Loubet 
et al., 2012) the expression of the prion protein. In this respect, cells that are generated from 
Prnp
−/−
 mice are especially valuable. While some Prnp
−/−
 cells are generated from mice with 
the ectopic expression of Doppel in the CNS (Kim et al., 2005; Kuwahara et al., 1999), Kim 
and coworkers (Kim et al., 2005) have established a series of cell lines , derived from primary 
neuronal cells of Zürich I Prnp−/−  (Zür I) mice (termed Zpl cells) and wild-type cell lines 
from ICR Prnp
+/+
 strain, which is the strain of origin of the Zür I mice (termed ZW cells)  that 
do not express the Dpl gene. The fact that expression of Dpl in the absence of PrP expression 
in vivo can cause neuropathological and clinical changes, certainly affects the usefulness of a 
cell line that is PrP
−/−
  and Dpl
+/+
 in studying the role of PrP in cellular physiology, which is 
not the case for the Zpl cell line. From these series of Zpl and ZW mouse hippocampal 
neuronal cell lines, here we used the Zpl 2-1(Prnp
−/−
) and ZW 13-2 (Prnp
+/+
) lines that have 
previously been fully characterized (Kim et al., 2005). Using these two cell lines we wanted 
to investigate whether the presence of PrP confers any general protection to the cells during 
transition metal stress.  
  
4.1 ZW 13–2 cells are significantly more resistant to Cu
2+
, Zn
2+
, 
Mn
2+
 and Co
2+
 induced toxicities than Zpl 2–1 cells 
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Before starting the studies on ZW 13-2 and Zpl 2-1 cells, we have verified the 
expression levels of the prion protein in the cell cultures maintained in our laboratory using 
immunoblotting and immunocytochemical analyses (Figure 6 and 7). The glycosylation of the 
prion protein is variable, resulting in un-, mono-, or diglycosylated forms, depending on the 
number of glycosylation sites occupied with oligosaccharide chains. The glycosylation of the 
PrP in our samples was verified by treatment with the amidase Peptide -N-Glycosidase F 
(PNGase F), which accordingly reduced the relative molecular mass of the protein, consistent 
with the removal of asparagine-linked glycans.  ZW 13-2 cells have a high level of PrP
C
 
expression with proper N-glycosylation, which is confirmed by both untreated and PNGase 
treated samples (lanes 1 and 2, Figure 6). Contrary, Zpl 2-1 cells are a knockout cell line with 
no expression of PrP
C
; accordingly, we have not found any detectable band for PrP on the 
immunoblot (lanes 3 and 4, Figure 6).   
 
Figure 6: Immunoblotting performed to verify expression levels of PrP in the ZW 13–2 
and Zpl 2–1 cell lines. Western blot of total cell lysates from wild type hippocampal neuronal 
cell line of ICR mice (ZW 13–2) and Prnp−/− hippocampal neuronal cell line of Zürich I mice 
(Zpl 2–1). Cell lysates were incubated either in the absence (lane 1 and lane 3) or in the 
presence of PNGase F (lane 2 and lane 4). Western blot analysis of PrP was carried out with 
monoclonal PrP antibody SAF 32. β-actin was used to confirm equal loading of proteins. 
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Expression and localization of the prion protein in the two cell lines was further tested by 
immunocytochemical analysis (Figure 7). For cell imaging, confocal laser scanning 
microscope Olympus Fluoview FV1000 was used. Microscope configuration such as laser 
intensity settings and two channel image-acquisition settings I had optimized during my Ph.D. 
while working on HeLa cells (Molnár et al., 2013)., and have used here similarly. The bright 
red immunofluorescence-staining pattern in the ZW 13-2 cells revealed that the prion protein 
was distributed on the surface of the cells, whereas no immunoreactivity was detected in the 
Zpl 2-1 cells.  
                               
 
Figure 7:  Immunocytochemistry verification of prion protein expression in ZW 13–2 
and Zpl 2–1 cells. PrP is immunolabeled by using the monoclonal PrP antibody SAF 32 with 
an Alexa 568 conjugated secondary antibody (red), nucleus is stained with DAPI (cyanine 
blue) and merged images are shown in the last column. Pictures were recorded by using a 60X 
oil immersion objective and a zooming factor of 4. Scale bar: 5 µm. 
 
To investigate the role of PrP
C
 under transition metals-induced toxicity, we examined 
Zpl 2-1 and ZW 13-2 cells under Cu
2+
, Zn
2+
, Mn
2+
 or Co
2+
 treatments using a range of 
concentrations of each metal ion and using alamarBlue-based cell viability assay. After 24 h 
of metal treatments of the cells with various ranges of concentrations, cells proved to be 
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sensitive at above 200 μM to copper, manganese and cobalt and above 50 μM in the case of 
zinc (Figure 8). Such concentration ranges of metals at which the toxicity is observable was 
found in other cell lines too (Choi et al., 2007; Perera and Hooper, 2001; Rachidi et al., 2009). 
Among the four metal ions, both cell lines were most sensitive to Zn
2+
 treatment showing 
significant differences in the number of surviving cells compared to the untreated controls 
even at 100 μM concentrations (Figure 8B). Cells were least responsive to Cu2+ treatment, 
since the cell viability started to decrease significantly only at 500 μM dose compared to 
untreated cells in case of both cell lines (Figure 8A). Nevertheless, Zpl 2–1 cells were 
significantly more susceptible to Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 toxicities than ZW 13–2 cells at 
all concentrations of the metal ions that fall into the toxic ranges for the cells (Figure 8). 
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Figure 8: Sensitivity to transition metal-induced toxicity of ZW 13–2 and Zpl 2–1 cells. 
Cells were tested for survival after treatment with transition metals for 24 h, assessing cell 
viability by alamarBlue assay. The cell lines ZW 13–2 (open circles) and Zpl 2–1 (black 
circles) were treated with increasing concentrations of either Cu
2+
-Gly (A) or Zn
2+
(B), or 
Mn
2+
 (C) or Co
2+
 (D). Values were compared to those of the untreated controls and are 
presented as   percentage. The data represent the means ± standard deviation (S.D.) of 
minimum 3 independent experiments performed in 5 replicates. *p<0.05, **p<0.01 and 
***p<0.001 indicate significant differences between treated and untreated 
cells; 
+
p<0.05, 
++
p<0.01 and 
+++
p<0.001 indicate significant differences between ZW 13–2 
and Zpl 2–1 cells 
 
Based on the results of the cell viability analyses comparing the two cell lines, we can 
conclude that the ZW 13–2 cells, possessing PrP, are significantly more resistant to Cu2+, 
Zn
2+
, Mn
2+
 and Co
2+ 
 induced toxicities than Zpl 2–1 cells. 
 
4.2 ZW 13–2 cells are morphologically less affected by Cu
2+
, Zn
2+
, 
Mn
2+ 
 and Co
2+ 
induced stresses than  Zpl 2–1 cells  
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Additionally, we investigated whether ZW 13–2 and Zpl 2–1 cell lines differed in their 
morphological features when exposed to various concentrations of Cu
2+
, Zn
2+
, Mn
2+
 and 
Co
2+
 treatments using light microscopy. The observed morphological features of ZW 13–2 
and Zpl 2–1 cells exposed to Cu2+, Zn2+, Mn2+ or Co2+ revealed irregular shrinkage and cell 
rounding as compared with the untreated control cells. In both cell lines the number of cells 
attached to the surfaces of culture dishes gradually decreased with increasing concentrations 
of transition metals. However, there were apparently fewer attached Zpl 2–1 cells than were 
ZW 13–2 cells, in a dose-dependent manner for Cu2+ (Figure 9), Zn2+ (Figure 10), Mn2+ 
(Figure 11) and Co
2+
 (Figure 12) treatments.  
 
 Figure 9: Morphological appearance of ZW 13-2 and Zpl 2-1 with Cu
2+
. ZW 13-2 and 
Zpl 2-1 cells, when treated with the indicated concentrations of Cu
2+
-Gly. Transmission light 
microscopy images of cells recorded using a 10X objective. Scale bar: 100 µm. 
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Figure 10: Morphological appearance of ZW 13-2 and Zpl 2-1 with Zn
2+
. ZW 13-2 and 
Zpl 2-1cells treated with the indicated concentrations of Zn
2+
. Transmission light microscopy 
images of cells, acquired using a 10X objective. Scale bar: 100 µm. 
 
 
 Figure 11: Morphological appearance of ZW 13-2 and Zpl 2-1 with Mn
2+
. ZW 13-2 and 
Zpl 2-1cells treated with the indicated concentrations of Mn
2+
. Transmission light microscopy 
images of cells acquired using a 10X objective. Scale bar: 100 µm. 
  
Figure 12: Morphological appearance of ZW 13-2 and Zpl 2-1 with Co
2+
. ZW 13-2 and 
Zpl 2-1 (A) and of Zpl 2-1-vector and Zpl 2-1-PrP (B) cells treated with the indicated 
concentrations of Co
2+
. Transmission light microscopy images of cells recorded using a 10X 
objective. Scale bar: 100 µm. 
 
These findings clearly demonstrate that PrP-expressing ZW 13-2 control cells are 
morphologically less affected by the Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 induced stresses than Zürich 
I Zpl 2-1 neuronal cells, the latter proving to be morphologically more susceptible to the same 
treatments.  
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In conclusion, based on cell viability analyses and morphological appearance, PrP 
expressing wild type ZW 13-2 cells were significantly more resistant to Cu
2+
, Zn
2+
, Mn
2+
 and 
Co
2+ 
induced toxicities than PrP-ablated Zpl 2–1 cells , which is consistent with the 
contention that PrP
C
 may play a protective role against Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 
cytotoxicity.. 
 
4.3 Generation of stable prion protein expressing Prnp
−/−
 (Zpl 2-1) 
neuronal cell lines  
To confirm whether the prion itself is solely responsible for the protective effect 
against transition metals induced toxicity found in the case of ZW 13-2 and Zpl 2-1 cells, we 
used the Prnp
−/− 
(Zpl 2–1) knock out cell line and re-introduce the Prnp gene into the cells, by 
stably transfecting it with a DNA construct encoding mouse PrP using the Sleeping Beauty 
(SB) transposase system. The SB transposase system mediated gene integration had been 
extensively studied and it is nowadays widely used to generate stable integrations of genes 
(Grabundzija et al., 2010; Kolacsek et al., 2014). It induces stable integration and reliable 
long-term expression of the gene of interest and its efficiency is higher than that of the 
random integration by up to two orders of magnitude.  The vector used in this study is 
designed so that it also contains an EGFP expression cassette to facilitate the selection of the 
cells with integrated transgenes. The coupled integration of the two expression cassettes (PrP 
and EGFP) between the transposon arms has been demonstrated, and it made feasible the 
selection of the successful transformants by FACS. Thus, instead of cloning the stably 
transfected cells, a cell population could be produced with various random sites of transgene 
integration, averaging out the potential positional effects of individual integrations on the 
outcome of the experiments. An only-EGFP-expressing vector was also used for the purpose 
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to generate control cells (Zpl 2-1-vector) along with the Zpl 2-1-PrP cells, in order to be able 
to rule out later the possibility of other factors than PrP
C
 expression alone, to play role in the 
restoration of protection against metals induced toxicity in Zpl 2-1 cells. 
By using Western blot and immunocytochemical analyses, we tested the expression of 
PrP
C
 in established Zpl 2-1-PrP and Zpl 2-1-vector cell lines. Total cell lysates of Zpl 2-1-
vector and Zpl 2-1-PrP hippocampal neuronal cells were collected and were either left 
untreated or were treated by PNGase F before immunoblotting with monoclonal PrP antibody 
SAF 32 (Figure 13). 
                                   
Figure 13: Western blotting performed to verify expression levels of PrP in the 
generated stable Zpl 2-1-vector and Zpl 2-1-PrP cell lines. Total cell lysates of stably 
expressing cells made from Prnp−/− hippocampal neuronal cell line of Zürich I mice (Zpl 2–
1) transfected with either the empty vector (Zpl 2-1-vector) or with mouse PrP gene (Zpl 2-1-
PrP). Cell lysates were incubated in the absence (lane 1 and lane 3) or presence of PNGase F 
(lane 2 and lane 4). Western blot analysis was carried out with monoclonal PrP antibody SAF 
32. β-actin was used to confirm equal loading of proteins. 
 
Zpl 2-1-PrP cells exhibit a well-detectable level of PrP
C
 expression. The detected bands were 
properly N-glycosylated as judged by the bands in the PNGase treated and untreated samples 
(lanes 1 and 2, Figure 13) whereas, The Zpl 2-1-vector cells, where there is no expected 
expression of prion, showed no detectable bands for PrP (lane 3 and 4, Figure 13). In addition, 
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prion expression and localization were confirmed by immunocytochemical analysis of the 
fixed cells (Figure 14). Cell imaging was performed  similarly as in the case of ZW 13-2 and 
Zpl 2-1 cells (Fig. 7) according to the method I had optimized  in Molnar et al. (Molnár et al., 
2013).  The bright red immunofluorescence-staining pattern in the Zpl 2-1-PrP cells revealed 
that the prion protein was distributed on the surface of the cells, whereas no immunoreactivity 
was detected in the Zpl 2-1-vector cells. 
 
  
Figure 14: Immunocytochemistry performed to verify prion protein expression in Zpl 2-
1- PrP and Zpl 2-1-vector cells. PrP is immunolabeled by the monoclonal PrP antibody SAF 
32 and an Alexa 568 conjugated secondary antibody (red), nucleus is stained with DAPI 
(cyanine blue) and merged image is shown in the last column. Pictures were recorded using a 
60X oil immersion objective and a zooming factor of 4. Scale bar: 5 µm. 
 
Microscopic pictures have also been taken at lower magnification in order to visualize 
the percentage of PrP expressing cells in the population. The number of transformant cells 
was estimated based on the microscopy pictures using the counts of DAPI stained cells as the 
total cells and the Alexa568 positive cells as counts of the transformant cells. We found that 
90(+/-1.7) % of the Zpl 2-1-PrP cells express PrP on the surface, whereas, we found no 
positively stained cells of the vector-expressing cells (Figure 15).  
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Figure 15: The percentage of PrP expressing cells in Zpl 2-1- PrP and Zpl 2-1-vector 
cells. (Pictures were recorded using a 60X oil immersion objective and a zooming factor of 1. 
Scale bar: 20 µm.) 
The expression levels of PrP
C
 in Zpl 2-1-PrP cells were also compared to the 
expression levels present in the wild type ZW 13-2 cells by using western blot analysis 
(Figure 16).  
 
 
Figure 16: The expression of PrP in ZW 13–2 and Zpl 2-1-PrP stable cell. Western blot 
analysis with the monoclonal PrP antibody SAF 32 in cell lysates from ZW 13-2 and Zpl 2–1 
transfected with mouse PrP gene (Zpl 2-1-PrP) cell lines.  β-actin was used to confirm equal 
loading of proteins.  
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Figure 16 shows three independent samplings (Exp-1,2,3) of the two cells where the total cell 
lysates collected at the three occasions were blotted at the same time to look for PrP. By using 
densitometry analysis, the bands corresponding to the prion protein
 
were normalized with the 
bands corresponding to the β-actin used as loading control on Fig 16,  and the PrP leves were 
quantified (Figure 17).          
 
                                    
Figure 17: Relative expressions of PrP from ZW 13–2 and Zpl 2-1-PrP cell lines. The 
expression of PrP
C
 is quantified using densitometry analysis, the bars represent the average 
value obtained from three independent western blots and the error bars represent the standard 
deviations. 
 
As can be seen on Figure 17 the prion protein expression levels were comparable in 
Zpl 2-1-PrP and ZW 13-2 cells.  
We can conclude that the generated stable Zpl 2-1-PrP transgenic cell line possesses 
comparable levels of PrP expression to the wild type ZW 13-2 cell line, and that the expressed 
PrP has similar localization and glycosylation to the PrP in the wild type cell, making the 
generated Zpl 2-1-PrP cell line suitable for a comparative study on the prion protein.     
 
4.4 Zpl 2–1-PrP cells are not significantly more resistant to Cu
2+
, 
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Zn
2+
, Mn
2+
and Co
2+
 induced toxicities than its control Zpl 2-1-
vector cells 
To verify whether the presence of cellular prion protein was the only accountable 
factor for the difference found in the susceptibilities of PrP-expressing ZW 13–2 cells  
and  Prnp
−/−
Zpl 2–1 cells against metal toxicity (Chapter 4.1 and 4.2), we treated Zpl 2-1-PrP 
and Zpl 2-1-vector cells characterized above (Figure 13-17) with the same metals Cu
2+
, Zn
2+
, 
Mn
2+
 and Co
2+
 at the same concentrations as on Figure 8 and assessed their survival using 
alamarBlue-based assay (Figure 18A, B, C and D).  
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Figure 18: The effect of the presence of PrP
C
 on the susceptibility of cells to transition 
metal-induced toxicity. Cells were tested for survival after treatment with transition metals 
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for 24 h and cell viability was determined using alamarBlue assay. Values are compared to 
those of the untreated controls and are expressed as percentage. The cells Zpl 2-1-PrP (open 
triangles) and Zpl 2-1-vector (black triangles) are compared (panels A through D) during 
treatments with increasing concentrations of metals, as follows: Cu
2+
-Gly (A), of Zn
2+
(B), 
Mn
2+
 (C) and Co
2+
 (D). The data are presented as means ± standard deviation (S.D.) of 
minimum 3 independent experiments performed in 5 replicates. *p<0.05, **p<0.01 and 
***p<0.001 indicate significant differences between treated and untreated cells on panels A 
through D; 
μ
p<0.05, 
μμ
p<0.01 and 
μμμ
p<0.001 indicate significant differences between treated 
Zpl 2-1-PrP cells and treated Zpl 2-1-vector cells.  
 
Treatment with these metals significantly decreased cell viability in both Zpl 2-1-PrP and Zpl 
2-1-vector cells compared to the untreated controls at the same metal ion concentrations. The 
concentration range where the cells proved to be sensitive to metal ion after a 24 h treatment 
was above 200 μM for Cu2+, Mn2+ and Co2+ (Figure 18A, C and D) and above 50 μM in the 
case of Zn
2+
 (Figure 18B). Among the four metal ions, cells showed to be the most sensitive 
to Zn
2+
 treatment, during which cell viability started to decrease significantly at as little as 
100 μM concentration compared to untreated cells in case of both cell lines (Figure 18B). PrP 
expressing Zpl 2–1-PrP cells showed to be significantly more sensitive to Zn2+ and 
Mn
2+
 induced toxicities than its control Zpl 2-1-vector cells but not in case of Cu
2+
 and Co
2+
 
treatments.   
These results show that the PrP expressing Zpl 2–1-PrP cells are not significantly 
more resistant to Cu
2+
, Zn
2+
, Mn
2+
and Co
2+
 induced toxicities than its control Zpl 2-1-vector 
cells, even though the PrP expression in Zpl 2-1-PrP cell line is present (and at a level 
comparable to that in the ZW cells), whereas in the Zpl 2-1-vector cell line it is not.  
After this puzzling finding we wanted to see how the viability levels of these two lines 
compare to the original Zpl 2-1 and wild type ZW 13-2 cells. The comparisons are presented 
on Figure 19.  
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Figure 19: Effect of PrP
C
 expression on the susceptibility of cells to Cu
2+
, Zn
2+
, Mn
2+
 and 
Co
2+ 
induced toxicity. Cells were tested for survival after treatment with transition metals for 
24 h and cell viability was determined using alamarBlue assay. Values are compared to those 
of the untreated controls and are expressed as percentage. The cell lines ZW 13–2 (open 
circles), Zpl 2–1 (black circles), Zpl 2-1-PrP (open triangles) and Zpl 2-1-vector (black 
triangles) were treated similarly with increasing concentrations of metals and all four types of 
cells are compared on panels A through D, as follows: increasing concentration of Cu
2+
-Gly 
(A), of Zn
2+
 (B), Mn
2+
 (C) and of Co
2+ (D). The data are presented as means ± standard 
deviation (S.D.) of minimum 3 independent experiments performed in 5 
replicates. 
+
p<0.05, 
++
p<0.01 and 
+++
p<0.001 indicate significant differences between the 
treated ZW 13–2 cells and treated Zpl 2–1 cells; δp<0.05, δδp<0.01 andδδδp<0.001indicate 
significant differences between the treated ZW 13–2 cells and treated Zpl 2-1-vector cells, 
and 
φ
p<0.05, 
φφ
p<0.01 and 
φφφ
p<0.001 indicate significant differences between the treated ZW 
13–2 cells and treated Zpl 2-1-PrP cells. 
 
Figure 19 also shows the estimated significances of the differences when making three 
kinds of comparisons: ZW 13-2 cells compared to Zpl 2-1 vector, Zpl 2-1-PrP, and Zpl 2-1 
cells. Overall we can observe that the  viability of Zpl 2-1-PrP and Zpl 2-1-vector cells are 
significantly lower than that of ZW 13–2 cells in case of Cu+2, Zn+2 and Co+2 treatment 
(Figure 19A, B and D), whereas no significant difference is observed in case of 
Mn
+2
 treatment (Figure 19 C).  
Given that the PrP expression levels of the two cell lines, ZW 13-2 and Zpl 2-1-PrP, 
are comparable these findings argue that PrP was not the sole reason for the increased 
resistance of ZW 13–2 cells compared to Zpl 2–1 cells when exposed to metal stresses. 
 
 
4.5 Zpl 2–1-PrP cells are not less affected morphologically by 
Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 induced stresses than its control Zpl 2-
1-vector cells 
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Subsequently, we tested whether the generated stable cell lines differed in their 
morphological features when exposed to different doses of Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 using 
light microscopy (Figures 20 through 23). The morphological features of Zpl 2-1-PrP and Zpl 
2-1-vector cells exposed to each of the four metals revealed irregular shrinkage and cell 
rounding compared to the untreated control cells. The number of cells attached to the surfaces 
of culture dishes gradually decreased in a dose-dependent manner for Cu
2+
 (Figure 20), Zn
2+
 
(Figure 21), Mn
2+
 (Figure 22) and Co
2+
 (Figure 23) treatments, and in a similar manner for 
both types of cells.  
 
Figure 20: Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Cu
2+
. Zpl 
2-1-vector and Zpl 2-1-PrP cells, when treated with the indicated concentrations of Cu
2+
-Gly. 
Transmission light microscopy images of cells recorded using a 10X objective. Scale bar: 100 
µm. 
 
Figure 21: Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Zn
2+
. Zpl 
2-1-vector and Zpl 2-1-PrP cells treated with the indicated concentrations of Zn
2+
. 
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Transmission light microscopy images of cells, acquired using a 10X objective. Scale bar: 100 
µm. 
 
Figure 22: Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Mn
2+
. Zpl 
2-1-vector and Zpl 2-1-PrP cells treated with the indicated concentrations of Mn
2+
. 
Transmission light microscopy images of cells acquired using a 10X objective. Scale bar: 100 
µm. 
 
Figure 23: Morphological appearance of Zpl 2-1-vector and Zpl 2-1-PrP with Co
2+
. Zpl 
2-1-vector and Zpl 2-1-PrP cells treated with the indicated concentrations of Co
2+
. 
Transmission light microscopy images of cells recorded using a 10X objective. Scale bar: 100 
µm. 
 
From these observations we can conclude that even though Zpl 2-1-PrP cells do 
express the prion protein at considerable levels, they are not significantly more resistant to 
Cu
2+
, Zn
2+
, Mn
2+
and Co
2+
 induced toxicities than its control Zpl 2-1-vector cells based on the 
morphological comparisons, since they appear to be similarly affected morphologically by 
these metal induced stresses.  
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4.6 Zpl 2-1-PrP cells are not more resistant to Cu
+2
, Zn
+2
 and Co
+2
 
induced cell death than Zpl 2-1-vector cells, whereas, PrP 
expressing ZW cells are more resistant compared to the PrP 
ablated Zpl 2-1 cells 
As a complementary approach to cell viability and cell morphological assays, we 
attempted to check the effect of the presence of PrP
C
 on transition metal-toxicity by assessing 
the extent of cell death caused by the metal treatment. ZW 13–2, Zpl 2–1, Zpl 2-1-PrP and 
Zpl 2-1-vector cells were treated with the four transition metal ions Cu
2+
, Zn
2+
, Mn
2+
 and 
Co
2+
 for a period of 24 h followed by measurement of cell death using Propidium Iodide (PI) 
exclusion assay. Zpl 2-1, ZW 13-2, Zpl 2-1-vector and Zpl 2-1-PrP cells were treated either 
with 750 µM Cu2+ , or with 100 µM of Zn2+, or 500 µM of Mn2+ or 750 µM of Co2+, 
respectively. Dead cells were stained with PI and the histograms obtained by flow cytometry 
analysis were compared between the treated and untreated cells in case of each metal 
treatment (Figure 24A, 25A, 26A and 27A, respectively).   
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Figure 24: The effect of the presence of PrP
C
 on Cu
2+ 
transition metal induced cell death. 
Cells were tested for cell death after treatment with transition metals for 24 h, cell death was 
measured by propidium iodide (PI) exclusion assay. (A) Zpl 2–1, ZW 13–2, Zpl 2-1-vector 
and Zpl 2-1-PrP cells were treated with 750 μM of Cu2+-Gly (1:4 mol/mol. Dead cells were 
stained with PI and histograms were obtained by flow cytometric analysis. M1 represents the 
population of PI positive cells. The bar graphs on the panel indicate the average of PI positive 
cells in case of 750 μM of Cu2+ treatment (B). Experiments were performed three times in 
duplicates, and data represent the mean ± standard deviation (S.D.). *p<0.05, **p<0.01 and 
***p<0.001 indicate significant differences between treated (+) and untreated (-) 
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cells; 
+
p<0.05, 
++
p<0.01 and 
+++
p<0.001 indicate significant differences between the ratios 
obtained for treated ZW 13–2 cells to treated Zpl 2–1 cells, and treated Zpl 2-1-vector cells to 
treated Zpl 2-1-PrP cells, respectively. 
 
Exposure to Cu
2+
, Zn
2+
, and Mn
2+
 for 24 h resulted in increase of PI positive cells in 
most cell lines and conditions as shown by the average number of PI stained dead cells on the  
B panels of the figures 24 through 26 (Figure 24B, 25B and  26B. However, the number of PI 
positive cells was significantly less in ZW 13-2 as compared to Zpl 2-1 cell lines in case of 
Cu
2+
, Zn
2+
 and Mn
2+
 (Figure 24B, 25B and 26B) but not in case of Co
2+
 treatments.  
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Figure 25: The effect of the presence of PrP
C
 on Zn
2+ 
transition metal induced cell death. 
Cells were tested for cell death after treatment with transition metals for 24 h, cell death was 
measured by propidium iodide (PI) exclusion assay. (A) Zpl 2–1, ZW 13–2, Zpl 2-1-vector 
and Zpl 2-1-PrP cells were treated with with 100 μM of Zn2. Dead cells were stained with PI, 
and histograms were obtained by flow cytometric analysis. M1 represents the population of PI 
positive cells. The bar graphs on the panel indicate the average of PI positive cells in case of 
100 μM of Zn2+ treatment (B). Experiments were performed three times in duplicates, and 
data represent the mean ± standard deviation (S.D.). *p<0.05, **p<0.01 and ***p<0.001 
indicate significant differences between treated (+) and untreated (-) cells; 
+
p<0.05, 
++
p<0.01 
and 
+++
p<0.001 indicate significant differences between the ratios obtained for treated ZW 
13–2 cells to treated Zpl 2–1 cells, and treated Zpl 2-1-vector cells to treated Zpl 2-1-PrP 
cells, respectively. 
 
Co
2+
 was not significantly toxic to either Zpl 2-1 or ZW 13-2 cells compared to 
untreated control cells (Figure 27B). In case of Zpl 2-1-vector and Zpl 2-1-PrP cells, however, 
such results could  not be observed; the Zpl 2-1-PrP cell population had significantly more PI 
positive cells compared to Zpl 2-1-vector cells when treated by Cu
2+
,  Zn
2+
 and Co
2+
 (Figure 
24B, 25B and 27B), with both cell lines being unresponsive to manganese treatment.   
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Figure 26: The effect of the presence of PrP
C
 on Mn
2+ 
transition metal induced cell 
death. Cells were tested for cell death after treatment with transition metals for 24 h, cell 
death was measured by propidium iodide (PI) exclusion assay. (A) Zpl 2–1, ZW 13–2, Zpl 2-
1-vector and Zpl 2-1-PrP cells were treated with 500 μM of Mn2+. Dead cells were stained 
with PI, and histograms were obtained by flow cytometric analysis. M1 represents the 
population of PI positive cells. The bar graphs on the panel indicate the average of PI positive 
cells in case of 500 μM of Mn2+ treatment (B). Experiments were performed three times in 
duplicates, and data represent the mean ± standard deviation (S.D.). *p<0.05, **p<0.01 and 
***p<0.001 indicate significant differences between treated (+) and untreated (-) 
cells; 
+
p<0.05, 
++
p<0.01 and 
+++
p<0.001 indicate significant differences between the ratios 
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obtained for treated ZW 13–2 cells to treated Zpl 2–1 cells, and treated Zpl 2-1-vector cells to 
treated Zpl 2-1-PrP cells, respectively.  
 
These data indicate that PrP
C
-expressing Zpl 2-1-PrP cells did not gain more 
resistance to any of the metals tested and at the concentrations applied, compared to PrP-
lacking Zpl 2-1-vector cells. 
 
 
Figure 27: The effect of the presence of PrP
C
 on Co
2+
 transition metal induced cell death. 
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Cells were tested for cell death after treatment with transition metals for 24 h, cell death was 
measured by propidium iodide (PI) exclusion assay. (A) Zpl 2–1, ZW 13–2, Zpl 2-1-vector 
and Zpl 2-1-PrP cells were treated with 750 μM of Co2+. Dead cells were stained with PI, and 
histograms were obtained by flow cytometric analysis. M1 represents the population of PI 
positive cells. The bar graphs on the panel indicate the average of PI positive cells in case of 
750 μM of Co2+ treatment (B). Experiments were performed three times in duplicates, and 
data represent the mean ± standard deviation (S.D.). *p<0.05, **p<0.01 and ***p<0.001 
indicate significant differences between treated (+) and untreated (-) cells; 
+
p<0.05, 
++
p<0.01 
and 
+++
p<0.001 indicate significant differences between the ratios obtained for treated ZW 
13–2 cells to treated Zpl 2–1 cells, and treated Zpl 2-1-vector cells to treated Zpl 2-1-PrP 
cells, respectively. 
 
From these observations we can conclude that the PrP expressing Zpl 2-1-PrP cells are 
not more resistant to Cu
+2
, Zn
+2
 and Co
+2
 induced cell death than Zpl 2-1-vector cells when 
assessing by propidium iodide (PI) exclusion cell death assay, whereas the PrP expressing 
wild type ZW cells prove to be more resistant to Cu
2+
, Zn
2+
 and Mn
2+
 treatments, but not Co
+2
 
treatment. 
 
4.7 SH-SY5Y-PrP cells are significantly more resistant to Cu
2+
 
and Mn
2+
 induced toxicities than SH-SY5Y and SH-SY5Y-vector 
cells 
In order to test the generality of the observation made using Zpl cells, namely that 
expression of PrP in itself did not restore or increase the resistance of the cells to transition 
metals’ toxicities; we performed similar experiments on another type of cell, the SH-SY5Y 
neuroblastoma cell line. These cells are known to possess very low to undetectable amounts 
of endogenous PrP. We have transfected these cells using the SB transposase system as in the 
case of the Zpl cells, with an expression vector containing the mouse PrP gene and as control 
with the same vector but without the PrP gene and established stable expressing cell lines 
from both populations: SH-SY5Y-PrP and SH-SY5Y-vector cells.  To test the developed 
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transgenic cell lines the appropriate expression level and the proper processing of the prion 
protein were tested in the established cell population using immunoblot and 
immunocytochemical analyses (Figure 28). Total cell lysates of SH-SY5Y-PrP and SH-
SY5Y-vector cells were collected and immunoblotted with monoclonal PrP antibody SAF 32 
(Figure 28A). The SH-SY5Y-vector cells, not expected to express PrP
C
, show no detectable 
bands for PrP, whereas, the SH-SY5Y-PrP cells, exhibit a well-detectable level of PrP
C
 
expression.  Expression and correct localization of the prion protein was further tested by 
immunocytochemical analysis (Figure 28B).  
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Figure 28: Prion protein expression levels in stable SH-SY5Y-vector and SH-SY5Y-PrP 
cell lines. (A) Western blot analysis was conducted using anti PrP antibody SAF 32 in total 
cell lysates from human neuroblastoma cell line (SH-SY5Y) transfected with either the empty 
vector (SH-SY5Y-vector) or with mouse PrP gene (SH-SY5Y-PrP). b-actin was used to 
confirm equal loading of proteins. (B) Immunocytochemistry was also performed to verify 
prion protein expression in the cells. Prion protein was stained with anti PrP antibody SAF 32 
and an Alexa 568 conjugated secondary antibody (red stain). Nuclear staining was performed 
with DAPI (cyanine blue) and merged image is shown in the last column. Pictures were 
recorded using a 60X oil immersion objective with 4X zooming. Scale bar: 5 µm. 
 
The bright red immunofluorescence-staining pattern in the SH-SY5Y-PrP cells revealed that 
the prion protein was distributed on the surface of the cells, whereas no immunoreactivity was 
detected in the SH-SY5Y-vector cells. For cell imaging, microscope settings and 
methodology were adapted from Molnar et al. (Molnár et al., 2013) similarly as in the case of 
the studies presented here on ZW and Zpl cells. 
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These results confirmed that the established SH-SY5Y-PrP cell line expressed 
considerable amount of PrP with proper glycosylation and localization in the cells, whereas 
the control cell line, as expected, did not have detectable amounts of PrP.  
 
To test whether there is any general protective role of PrP
C
 against transition metals-
induced toxicity in this type of cellular model system, we aimed to assess if the three cell lines 
differed in sensitivity to Cu
2+
, Zn
2+
, Mn
2+
 or Co
2+
 treatments, using a range of concentrations 
of each metal ion and the alamarBlue-based cell viability assay, similarly as in the case of Zpl 
and ZW cells was used. The results obtained for each metal treatment are shown on Figure 29 
as separate panels.  
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Figure 29: Effect of PrP
C
 expression on resistance to transition metal-induced toxicity. 
Cells were tested for survival after treatment with transition metals for 24 h, assessing cell 
viability by alamarBlue assay. The cell lines SH-SY5Y - PrP (open triangles), SH-SY5Y - 
vector (black squares) and SH-SY5Y (open squares) were treated with increasing 
concentrations of either Cu
2+
-Gly  (A), or Zn
2+ 
(B), or Mn
2+
 (C) or Co
2+ 
(D). Values were 
compared to those of the untreated controls and are presented as percentage. The data 
represent the means ± standard deviation (S.D.) of 3 independent experiments performed in 5 
replicates. *p<0.05, **p<0.01 and ***p<0.001 indicate significant differences between 
treated and untreated cells; 
+
p<0.05, 
++
p<0.01 and 
+++
p<0.001 indicate significant differences 
between SH-SY5Y-PrP and SH-SY5Y–vector cells; δp<0.05, δδp<0.01 and δδδp<0.001 
indicate significant differences between SH-SY5Y-PrP and SH-SY5Y cells. 
 
Among the four metal ions, cells proved to be least responsive to Mn
2+
 treatment, during 
which cell viability started to decrease significantly only at 500 µM dose compared to 
untreated cells in case of the three cell lines (Figure 29C). All three cell lines are most 
sensitive to Zn
2+ 
treatment showing significant differences in the number of surviving cells 
compared to the untreated controls at as little as 50 µM dose (Figure 29B). Nevertheless, SH-
SY5Y-vector cells were significantly more susceptible to Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 toxicities 
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than SH-SY5Y-PrP cells at all concentrations of the metal ions that fall into the toxic ranges 
for the cells (Figure 29A through D), also, compared to the original SH-SY5Y cells they show 
significantly less susceptibility in case of Zn
2+
 and Co
2+
 but not Cu
2+
 and Mn
2+
 induced 
toxicities. 
 We have selected SH-SY5Y human neuroblastoma cells as another model system to 
investigate the role of PrP in metal-induced toxicity because they have very low PrP 
expression levels, and hence could serve as a “PrP-null” cell line, where the role of PrP may 
be studied if generating PrP-expressing transgenic line from it and comparing the behavior of 
the cells to the control population during stress conditions. When we generated PrP-
expressing  and control vector-only-expressing cell lines from these cells, we found that PrP 
expressing SH-SY5Y-PrP cells are in general significantly more resistant to Cu
2+
, Zn
2+
 and 
Mn
2+
 induced toxicities, than SH-SY5Y-vector cells or SH-SY5Y cells. These results seem to 
argue for a protective role of PrP against metal induced toxicities in this SH-SY5Y cell type 
based cellular model system. 
 
 
 
 
 
 
 
 
 
 
67 
 
5. Discussion 
Oxidative stress and programmed cell death have been implicated in a number of 
neurodegenerative disorders including prion disease (Choi et al., 2006; Kanthasamy et al., 
2003; Tritschler et al., 1994). It has been known that there is a certain affinity of several 
transition metals towards PrP
C
 and that the transition metal-PrP
C
 interaction might have an 
effect on PrP
C
 biology. It has been theorized that the binding of certain transition metals such 
as Cu
2+
 and Zn
2+
 to PrP
C
 induces the endocytosis of the latter, which might be a signal 
triggering antioxidative defense. Nevertheless, although the mechanism is not clear, a 
protective role against toxicity conferred by transition metal ions has been suggested for the 
prion protein in cell culture model systems (Choi et al., 2007; Haigh and Brown, 2006; 
Rachidi et al., 2009). In the present study, we explored a Prnp
-/-
 neuronal cell line (Zpl 2–1) 
of hippocampal origin as a model system, along with its PrP expressing control ZW 13–2 
cells. Zpl 2–1 has been shown to be more vulnerable to serum deprivation and oxidative 
damage induced by H2O2 than its PrP-expressing counterpart (Kim et al., 2004; Oh et al., 
2008, 2012). Reintroduction of PrP restored the viability of Zpl cells, thus, it seems to be a 
relevant model for assessing the effect of PrP
C
 on metal-induced toxicity as well. Hence, we 
studied whether PrP has any general protective effect against transition metal toxicity, testing 
Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 toxicities.  
Metals might exert their toxic effects via multiple routes and PrP
C
 has been reported to 
interfere with a handful of pathways leading to cell death (Bounhar et al., 2001; Khosravani et 
al., 2008; Lee et al., 2001b; McLennan et al., 2004; Vassallo and Herms, 2003).Therefore we 
chose methods such as alamarBlue viability assay and propidium iodide-based dye exclusion 
assay to examine the viability of the cells by the application of various concentrations of the 
four transition metals, rather than considering the mechanisms of protective pathways.  
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The alamarBlue is a cell viability assay reagent which contains the cell permeable, non-toxic 
and weakly fluorescent blue indicator dye resazurin, which is used as an oxidation-reduction 
(REDOX) indicator in response to cellular metabolic reduction.  AlamarBlue can be reduced 
by FMNH2, FADH2, NADH, NADPH and cytochromes and hence is an redox indicator for 
cell proliferation and viability studies because it does not interfere in any way with the 
reactions of the electron transport chain (Rampersad, 2012).  By contrast, the nucleic acid 
staining dye propidium iodide, cannot pass through a viable cell membrane. It reaches the 
nucleus by passing through disordered areas of dead cell membranes. 
According to the results presented here, PrP-expressing ZW cells are found to be more 
resistant to all four transition metals than PrP-ablated Zpl cells. These results suggest that PrP 
has a protective role against metal induced toxicity not only against Cu
2+
, Mn
2+
 and Zn
2+
 but 
also against Co
2+ 
for which such role has not been reported (Haigh and Brown, 2006; Rachidi 
et al., 2009).  
Interestingly, we found quite surprising results while establishing more define link 
between PrP-expression and vulnerability to transition metal induced toxicity. PrP 
reintroduction in Zpl cells failed to give any significant increase in resistance against Cu
2+
, 
Mn
2+
, Zn
2+
 and Co
2+ 
induced toxicities by all three approaches. Hence, in the presence of 
metal toxicity, we could not find a clear link between the prion protein expression and a 
decreased sensitivity. These are interesting results, since, PrP has been reported to protect 
cells from copper (Haigh and Brown, 2006), manganese (Choi et al., 2007) or zinc (Rachidi et 
al., 2009) metal toxicity by using other cell model systems and approaches. Most of the 
studies concerning PrP
C
-copper interactions focused on the actual binding event taking 
place in vitro, monitored the internalization of PrP
C
 upon exposure to Cu
2+
 as a direct 
indication of in vivo PrP
C
-Cu
2+
 interaction and/or run assays to show the impact of the 
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ablation of PrP
C
 expression on steps of the oxidative stress response (Brown et al., 1997d; 
Haigh and Brown, 2006; Pauly and Harris, 1998). So far only one study has aimed to examine 
if PrP
C
 expression can confer resistance against copper induced toxicity. Haigh and Brown 
investigated in F14 cell based models the potential of PrP to protect cells against copper 
toxicity and found that PrP expression effectively protected F14 cells from copper toxicity. 
(Haigh and Brown, 2006). They also reported that copper when chelated with glycine, 
generates no ROS and does not trigger oxidative cell response.  However, the toxicity due to 
the "nonoxidative components" of copper toxicity was also inhibited by expression of PrP  In 
case of Mn
2+
, they found no difference between the toxic effects of the treatments with or 
without glycine although there is a weaker chelation between Mn
2+
 and glycine. Nevertheless, 
at higher concentrations of manganese, PrP
C
 expressing F14 cells showed less vulnerability to 
Mn
2+ 
toxicity. Interestingly, in the same study, with or without PrP
C
 expression, F14 cell lines 
exhibited no different viability when incubated with various concentration of Zn
2+
 (Haigh and 
Brown, 2006). The studies of Choi and coworkers supported the previous results of Haigh and 
Brown on manganese, while examining mouse CF10 neural cell lines expressing prion protein 
(PrP
C
-cells) and the prion-knockout (PrP
KO
-cells) cells. Mn
2+
 treatment induced mitochondrial 
depolarization and ROS generations were significantly decreased in PrP expressing cells as 
compared to PrP
KO
-cells and Mn
2+
 treatment caused greater depletion of GSH in PrP
KO
-cells. 
Mn
2+
-induced mitochondrial depolarization and ROS production were followed by activation 
of the apoptotic cell death cascade involving caspase-9 and 3 in PrP
KO
 CF10 cell line (Choi et 
al., 2007).. Interestingly, analysis of intracellular Mn
2+
 levels showed less Mn
2+
 accumulation 
in PrP
C
-cells as compared to PrP
KO
-cells, and they concluded that PrP
C
 likely interferes with 
the uptake of Mn
2+
 (in addition to its effect on oxidative cell response) (Choi et al., 2007). 
Regarding Zn
2+
, Rachidi et al. studied the relationship between PrP and zinc ion intracellular 
homeostasis using a heterologous epithelial A74 cell line expressing a doxycycline-inducible 
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PrP gene, and in contrast to the results of Haigh and Brown (Haigh and Brown, 2006),found 
that cells would become more resistant to Zn
2+ 
toxicity when PrP-expression was induced 
(Rachidi et al., 2009).They suggested that PrP
C 
mediates intracellular redistribution of the 
interchangeable Zn
2+
 rather than interfering with cellular Zn
2+
 uptake. Furthermore, they put 
forward an explanation how PrP protects metal induced oxidative stress response: PrP
C
 
expression induces metallothionein (MT) expression, a zinc-upregulated zinc-binding protein, 
which sequesters metals thereby decreasing their ROS generating capacity.  
It is not easy to organize all the existing data into a comprehensible interpretation. The 
cell lines used in these studies had been derived from different tissues and species. A74 cells 
are from rabbit kidney while the mouse neuronal cells are from cerebellar (F14) or 
hippocampal (Zpl) origins. Thus, these results might reflect the various roles PrP plays in 
defending the cells against toxicity induced by the four transition metals investigated.  
It is also clear that metal induced toxicity involves complex and divergent pathways 
where subtle differences that are not apparently related to the transgene-expression, alter 
significantly the sensitivity of the cells. For example, Zpl cells become more resistant to 
Mn
2+
 treatment by the introduction of the vector control expressing only a GFP protein 
(Figure 19C and 26). Haigh and Brown found similar effects: vector control cells, expressing 
only a GFP protein, became significantly more resistant to Cu
2+ 
treatment in F14 cells, as 
apparent, if one compares Fig 3a and b in their results (Haigh and Brown, 2006).What they 
found is a greater difference than the one they observed as a consequence of PrP expression 
between the viability of the GFP-GPI and GFP-PrP cell lines (Fig 3a and 3b in (Haigh and 
Brown, 2006)).  
 Therefore, it is also possible that the effect of PrP expression on these transition metal 
toxicities is just not robust enough to be distinguishable in all cases.  
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Concern might be in our studies about the use of the CAG promoter instead of the 
natural PrP promoter. The expression levels of PrP in Prnp stable transgenic Zpl-PrP cells and 
wild type ZW cells are quite modest and comparable. However, the regulation of the PrP 
promoter is not displayed by this construct. Out of the four metals tested in this study, copper 
and manganese are reported to increase expression levels of the prion protein but not zinc. 
Thus, this is not a likely mechanism for providing a general protection against transition 
metals. In addition to it, Haigh and Brown employed CMV promoter whereas Rachidi et al 
used a doxycycline inducible TRE promoter, none of them is able to provide a regulation 
similar to that of the natural PrP promoter, yet, found a protective effect of PrP against 
copper, manganese and zinc toxicity, respectively. This further supports that the artificial 
promoter used is not the reason of the lack of PrP’s protective effect in our experiments. 
Another factor to be taken into consideration while compiling the different data 
available might be the differences in the methods used. The viability was monitored with 
MTT assay for F14, CF10 and A74 cells. Cell death for CF10 cells was determined by the 
Trypan blue exclusion method. Zpl cells were assayed in our study by both approaches, using 
an alamarBlue viability test and a propidium iodide exclusion method. Even when we 
compared the same metal (Mn
2+
) for the same cells (Zpl 2-1-PrP and ZW 13–2), interestingly, 
the relative sensitivities of the cells varied with the two methods used. Zpl 2-1-PrP cells were 
found more sensitive when assayed for cell viability (alamarBlue) and less sensitive when 
assayed by dye-exclusion (propidium-iodide) than ZW 13–2 cells (Figure 19C and 26). The 
two methods appeared not to give fully consistent results; the differing outcomes may 
partially be due to the fact that the two methods monitor different consequences of the metal 
treatments. The propidium iodide dye-exclusion method measures the actual percentages of 
the dead cells at a given time point, while the alamarBlue viability test measures 
metabolically active cells surviving a one-day treatment relative to that of the untreated cells. 
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Also, if one compares the vector cells to the PrP-expressing cells, treatments with three metals 
(copper, zinc and cobalt) resulted in altering sensitivities when examined with the two 
methods. The vector cells treated by cobalt are significantly more resistant than the PrP-
expressing cells when examined by propidium iodide while there is no significant difference 
between them when the cell viability assay is performed. By contrast, in case of the 
manganese treatment they prove to be more resistant than PrP-expressing one when assessed 
by viability assay, but there is no significant difference between the cell lines when probed by 
the propidium iodide method. In contrary, against copper the PrP-expressing cells are 
marginally significantly more resistant compared to the vector control cells when assayed by 
propidium iodide while no difference is detected in the cell viability assay. Interestingly, only 
in case of the zinc treatment and only the vector expressing cells show resistance by both 
techniques, with propidium iodide and with alamarBlue assays, at 100 μM concentration at 
which the propidium iodide experiments were conducted (Figure 25) From these 
observations, two points may be made: the relative sensitivities of the four cells on Figure 18 
and 19  are varied among the four metals, which in turn suggest no identical mechanism of 
actions nor common way of interference for PrP. These results also show that the methods 
used might be influential, and these might contribute to the differences seen in respect to the 
role of PrP in transition metal toxicities of F14, CF10, A74 and Zpl cells (Choi et al., 2007; 
Haigh and Brown, 2006; Kim et al., 2005; Rachidi et al., 2003b).  
We also need to consider that Haigh and Brown used a GFP-PrP fusion protein. We 
found that the activity of a mutant PrP might be impaired by a fluorescent protein fusion tag; 
specifically, a ΔCR PrP (Delta105-125) confers drug hypersensitivity to the cells in the 
absence of WT-PrP (Massignan et al., 2010), whereas, fusion of the fluorescent protein to 
ΔCR PrP abolishes this effect (unpublished result). In contrast to this, the internalization of N-
terminally fused GFP-PrP in response to Cu
2+
 stimuli is similar to the WT protein (Lee et al., 
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2001b). Thus, it is likely that PrP-metal interactions are not disturbed by the N-terminal GFP 
tag, however, it might influence the interactions of PrP with other cell constituents. 
Another critical issue is the possibility of a site specific effect of the integration of the 
transgene and the possible clonal variability. Here we have used only a single gene integration 
approach, the sleeping beauty (SB) transposase, to generate stabile integrations of the 
expression cassettes. SB transposon-based transfection is a two-component system consisting 
of a transposase and a transposon containing inverted repeat (IR) sequences that result in 
precise integration into a TA dinucleotide. The transposon is designed with an expression 
cassette of interest flanked by IRs, and SB transposase mediates stable integration and reliable 
long-term expression of the gene of interest. Its efficiency is higher than that of the random 
integration by up to two orders of magnitude. In our study, using sleeping beauty resulted cell 
populations with a few thousands of independent cells with unique integration sites. Thus, 
considering the size of the human genome, the likeliness that any gene involved in PrP 
associated resistance against metal toxicity is invalidated by the transgene integrations is very 
low. Conceivably, such subpopulation is much smaller than 1%. In addition, Figure 15 shows 
that close to 100% of Zpl-PrP cells express PrP, suggesting that only very few positions of the 
thousands of integrations interfere with the transgene expression ruling out the possibility that 
a non-expressing sub population muddies the cumulative protective involvement of PrP in the 
cellular response to divalent cations.  
We extended our study to another cell model system, the SH-SY5Y cells where 
similarly to Zpl cells,   we introduced prnp gene or the vector alone by the SB transposase 
method and generated PrP-expressing and control cells.  When performing similar metal 
toxicity tests like in the case of Zpl and ZW cells, the PrP-expressing SH-SY5Y-PrP cells 
were seen to be more resistant against toxicities of all four metals, as compared to SH-SY5Y-
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vector cells or the SH-SY5Y mother cells, when tested by alamarBlue viability assays. These 
results seem to support a protective role for PrP against transition metal of Cu
2+
, Mn
2+
, 
Zn
2+
 and Co
2+
 similarly to the observations made in case of ZW and Zpl cells and contrary to 
Zpl-PrP cells. These observations have also revealed that the protective effect in Zpl-vector 
cells against metal induced toxicity is neither because of the sleeping beauty (SB) transposase 
based integration nor because of the vector control expressing only GFP protein. 
By contrast, unlike in the case of a SB transposase based integration, F14/GFP-GPI, 
F14/GFP-PrP, CF10/PrP
C
, CF10/PrP
KO
 and A74 cell lines were derived from a few unique 
integration sites. Without examining cell lines originating from different clones it is difficult 
to rule out a possible effect of the integration sites on the outcome of the experiments. 
Nevertheless, it is apparent from this short review of the available data that there is no single 
technical factor that could explain appropriately these seemingly incoherent results. It is 
likely, that if PrP
C
 has any measurable impact on the complex and divergent pathways of 
metal toxicity, it is not a robust, general effect that is easily discernible in all types of cells. 
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6. Conclusions 
 When testing the toxic effects of Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
  on the mouse 
hippocampus-derived PrP-expressing ZW and the PrP-KO Zpl cells, we found that:  
 PrP expressing wild type ZW 13–2 cells are significantly more resistant to Cu2+, Zn2+, 
Mn
2+
 and Co
2+
 induced toxicities than PrP- ablated Zpl 2–1 cells, and also they 
are morphologically less affected by Cu
2+
, Zn
2+
, Mn
2+ 
 and Co
2+ 
induced stresses than 
PrP- ablated Zpl 2–1 cells.  
When introducing PrP-expression into PrP-ablated Zpl cells in an attempt to draw a 
more definite link between PrP expression and cellular resistance against metal 
toxicities we found that: 
 PrP expressing Zpl 2–1-PrP cells are not significantly more resistant to Cu2+, Zn2+, 
Mn
2+
and Co
2+
 induced toxicities than its control Zpl 2-1-vector cells, and also, are not 
less affected morphologically by Cu
2+
, Zn
2+
, Mn
2+
 and Co
2+
 induced stresses than its 
control Zpl 2-1-vector cells.  
 PrP expressing Zpl 2-1-PrP and its control Zpl 2-1-vector cells are more susceptible to 
Cu
+2
, Zn
+2
 and Co
+2
 toxicity than ZW 13-2 cells. 
 Zpl 2-1-PrP cells are not more resistant to Cu+2, Zn+2 and Co+2 induced cell death than 
Zpl 2-1-vector cells.  
When testing the effects of Cu2+, Zn2+, Mn2+ and Co2+  on another cell model system, 
the SH-SY5Y human neuroblastoma cells (that have very low PrP expression levels) 
and SH-SY5Y cells with induced PrP-expression or induced vector-only-expression, 
we found that: 
 PrP expressing SH-SY5Y-PrP cells are significantly more resistant to Cu2+ and Mn2+ 
induced toxicities than SH-SY5Y and SH-SY5Y-vector cells. 
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Although ZW cells established from WT mice are more resistant to all four metal ions 
tested, we could not establish a clear link between prion protein expression and an increased 
resistance to metal toxicity, since PrP expression does not confer increased resistance to Zpl 
cells as compared to GFP expression alone. Thus, the increased resistance of ZW cells are 
either not related to PrP
C
 expression, or at least PrP
C
 expression is not a sole factor necessary 
for the increased resistance. In SH-SY5Y cells elevated levels of PrP-expression confer higher 
resistance to metal toxicities compared to the wild type or the vector-only-expressing cells. 
Altogether, our results do not seem to support a general protective role for PrP against 
transition metal toxicity and also, we emphasize the necessity of extreme care when 
comparing cells derived from PrP knock-out and wild type mice. 
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9. Summary 
The interactions of transition metals with the prion protein (PrP) are well-documented 
and described; however, there is no consensus on their role in either the physiology of PrP or 
PrP-related neurodegenerative disorders. Reports revealed an interaction of PrP with 
transition metals and showed a protective role of PrP
C
 against cellular stresses, especially, 
against oxidative damage, which is perhaps one of the most widely accepted functions of 
PrP
C
. Zpl cells are hippocampus-derived Prnp
-/-
 immortalized cells that have been shown to 
be more vulnerable to apoptotic cell death than their PrP
C
-expressing counterparts. Here we 
used this model system to investigate whether these cells lacking PrP are more vulnerable to 
metal-induced toxicities as well. We selected four metals Cu
2+
, Mn
2+
, Co
2+
 and Zn
2+
 and used 
the alamarBlue viability assay and a propidium iodide-based dye exclusion assay, along with 
examining the overall morphological changes induced by the application of various 
concentrations of the four transition metals.  
PrP-expressing ZW cells established from WT mice were shown to be more resistant 
to all four metal ions tested in comparison to Prnp
-/-
 Zpl cells. Further, we introduced PrP or 
only the empty vector into Zpl cells by sleeping beauty (SB) transposase based system to 
generate stabile transgenic cell lines (Zpl 2–1-PrP and Zpl 2-1-vector cells). PrP-expressing 
Zpl 2–1-PrP cells did not show any increased significant resistant to Cu2+, Zn2+, Mn2+and 
Co
2+
 induced toxicities than its control Zpl 2-1-vector cells and we could not recognize any 
protective effects associated with the presence of PrP. This observation was further 
corroborated when assessing the toxic effect of metals by propidium-iodide staining and 
fluorescence activated cell sorting analysis. Based on these results we could not establish a 
clear link between prion protein expression and an increased resistance to metal toxicity that 
is seen in the case of ZW cells, since PrP expression does not confer increased resistance to 
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Zpl cells as compared to GFP expression alone. Thus, the increased resistance of ZW cells are 
either not related to PrP
C
 expression, or at least PrP
C
 expression is not the sole factor 
necessary for the increased resistance.  
 When the same studies were performed using SH-SY5Y cell line, a neuroblastoma 
model system, PrP expression rendered the cells more resistant against Cu
2+
 Zn
2+
, Mn
2+
 and 
Co
2+
 compared to vector expressing control cells at all concentrations of the metal ions that 
fall into the toxic ranges for the cells.Also, they showed significantly more resistance if 
compared to the mother SH-SY5Y cells. 
 Altogether, our results do not seem to support a general protective role for PrP 
against transition metal toxicity and also, we emphasize the necessity of extreme care when 
comparing cells derived from PrP knock-out and wild type mice. 
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10. Összefoglalás 
A prion fehérje (PrP) átmeneti fémekkel való kölcsönhatása jól dokumentált, számos 
vizsgálati eredmény írja le kölönböző aspektusait. Ennek ellenére nincs konszenzus a 
tekintetben, hogy ezek a kölcsönhatások pontosan milyen fiziológiás szerepet töltenek be, 
valamint, hogy milyen kapcsolatban állnak a neurodegenaratív betegségekkel. Az egészséges, 
celluláris PrP (PrPC) számos eddig leírt, valószínűsített funkciója közül talán a 
stresszhatásokkal szembeni sejt-védelem, ezen belül főleg az antioxidáns szerep az ami 
leginkább dokumentált. Tekintve, hogy az átmeneti fém-toxicitás a szabadgyökök generálásán 
keresztül valósul meg, valamint, maga a prion fehérje fémkötőhelyekkel rendelkezik, 
elképzelhető, hogy a PrPC a fémtoxicitás elleni védelemben is szerepet játszik. A Zpl sejtek 
egér hippocampus -eredetű Prnp- / - immortalizált sejtek, amelyekről kimutatták, hogy 
érzékenyebbek az apoptotikus sejthalálra mint a PrP -t expresszáló kontroll sejtek. Ezt a 
sejtkultúra-modellrendszert választottuk ki a jelen munkában, annak vizsgáltára, hogy vajon a 
fémtoxicitással szemben is érzékenyebbek-e a Prnp- / - sejtek. A vizsgálatokhoz négy 
különböző átmeneti fémet választottunk ki: Cu2+, Mn2+, Co2+ és Zn2+, melyeket különböző 
kocentrációkban alkalmaztunk, és három különböző vizsgálati módszert: az alamarBlue-alapú 
esszét a sejtek életképességének vizsgálatára, a propídium jodid festék-kizárás módszerét az 
elpusztult sejtek megbecsülésére, valamint, mikroszkópos morfológiai vizsgálatokat, a sejtek 
állapotának a morfológiai jellemzőkön keresztüli nyomonkövetésére. 
Kimutattunk, hogy a PrP -t expresszáló ZW kontroll sejtvonal, melyet a vad típusú 
(WT) egerekből hoztak létre, jobban ellenáll mind a négy tesztelt fémion hatásának a Prnp- / - 
Zpl sejtekhez képest. Továbbá, bevezetettük a PrP gént, vagy csak az üres vektort, Zpl 
sejtekbe csipkerózsika (SB) transzpozáz-fehérje alapú rendszert alkalmazva, és stabil 
transzgenikus sejtvonalakat hoztunk létre (Zpl 2-1-PrP és Zpl 2-1 -vektor sejtek). Azt találtuk, 
hogy a PrP-t expresszáló Zpl 2-1 -PrP transzgenikus sejtek nem mutattak semmilyen 
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jelentősen megnövekedett rezisztenciát a  Cu2+, Zn2+ , Mn2+ és Co2+ által indukált toxicitással 
szemben, a kontroll Zpl 2-1 - vektor sejtekhez képest, a PrP jelenlétének semmilyen mentő 
hatását nem tapasztaltuk. Ezt a megfigyelést támasztotta alá a propidium jodid alapú 
fluoreszcens sejtanalízis eredménye is amikor ugyanazon fémek toxicitását teszteltük ezzel a 
módszerrel. Az eredményeink alapján így nem tudtunk közvetlen párhuzamot vonni a PrP 
jelenléte és a fémek toxicitásával szembeni, ZW sejtek esetében tapasztalt, megnövekedett 
ellenállóképesség között, mivel hogy a PrP-expresszáló transzgenikus sejtvonal a vektor-, 
csak GFP-t expresszáló sejtvonalhoz képest, nem mutatott rezisztenciát a fémekkel szemben. 
Ezek alpján azt a következtetést vonhatjuk le, hogy a ZW sejtek esetében tapasztalt 
fémionokkal szembeni magasabb rezisztencia a PrP-null sejtvonalhoz képest, vagy nem a PrP 
jelenlétének tulajdonítható, vagy legalábbis a PrP jelenléte nem az egyedüli faktor ami a 
fémek toxicitásával szembeni ellenálását meghatározza.  
Amikor ugyanazon vizsgálatokat egy neuroblasztóma modell rendszeren az SH-SY5Y 
sejtvonalon végeztünk, a PrP-t expresszálló transzgenikus sejtvonal ellenállóbbá tette a 
sejteket a Cu
2+
 Zn
2+
, Mn
2+
 és Co2+ hatásával szemben, a csak vektort expresszáló kontroll 
sejtekhez képest, valamennyi azon fémion koncentrációk esetében melyek a toxikus 
tartományokba estek. A PrP-t expresszáló sejtek szignifikánsan nagyobb ellenállást mutattak 
az anya, SH- SY5Y, sejtekkel összehasonlítva is. 
Összevetve, eredményeink nem támasztják alá azt, hogy a prion fehérje általános 
mentő-szerepet töltene be fém-toxicitás esetén. E mellett, felhívja a figyelmet arra, hogy 
hasonló vizsgálatok során körültekintőnek kell lenni arra, hogy megfelelő kontroll 
sejtrendszereket válasszunk a vizsgálatokhoz.  
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Laboratory of Conformational Diseases of Ervin Welker, between 2010-2015 at the Institute 
of Biochemistry, BRC, Szeged. Majority of the experiments were conceived, designed and 
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